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ABSTRACT 
 
 The mammalian target of rapamycin (mTOR) is a Ser/Thr kinase with remarkable 
control over cellular status. As a master regulator, mTOR integrates a variety of intra- and 
extra-cellular signals in order to coordinate them with appropriate gene expression, protein 
synthesis, metabolism, cell migration, autophagy – the list goes on! mTOR signaling, with 
involvement in so many important cellular processes, can have detrimental physiological 
effects when dysregulated. Aberrant mTOR signaling is now known to contribute to a great 
number of the major pathologies we face today. Understanding how mTOR is normally 
regulated is, therefore, important for informing the development of effective and specific 
therapeutics for diseases like cancer and diabetes. Significant research efforts over the last 
two decades have informed our current understanding of the extensive mTOR signaling 
pathways, but many questions remain. In my dissertation work I have investigated long-
standing mysteries of mTOR activation by mitogens and nutrients, with specific focus on the 
mechanism by which the lipid second messenger, phosphatidic acid, activates mTOR 
complex 1. 
 The mammalian target of rapamycin complex 1(mTORC1) is regulated, in part, by 
the endogenous inhibitor DEPTOR. However, the mechanism of DEPTOR regulation with 
regard to rapid mTORC1 activation remains unknown. In collaboration with Dr. Mee Sup 
Yoon, I discovered that DEPTOR is rapidly and temporarily dissociated from mTORC1 upon 
mitogenic stimulation. We demonstrated that this mitogen stimulated DEPTOR dissociation 
is blocked by inhibition or depletion of the mTORC1 regulator, phospholipase D (PLD), and 
is recapitulated with the addition of the PLD product phosphatidic acid (PA). Parallel mass 
spectrometry analysis independently identified DEPTOR as an mTOR binding partner 
dissociated by PA. Interestingly, I found that only PA species with unsaturated fatty acid 
chains, such as those produced by PLD, are capable of displacing DEPTOR and activating 
mTORC1, with high affinity for the FRB domain of mTOR. Our findings, detailed in 
Chapter II reveal a mechanism of acute mTORC1 regulation that was previously unidentified 
and provide a molecular explanation for the exquisite specificity of PA function. 
 In light of PA’s essential role in mTORC1 activation, I found it striking that mTOR 
proteins containing one of several point mutations have been reported to remain catalytically 
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active in conditions when amino acids, and therefore PA, are absent. The existence of such 
hyperactive mTOR prompted me to ask whether a point mutation can render mTOR 
independent of regulation by PA and, if so, by what mechanism? In Chapter III, I describe 
how by examining the activity of several mTOR proteins each carrying a unique point 
mutation known to be associated with human cancer, I discovered that individual point 
mutations can confer varying degrees of PA-independent mTORC1 activity. My finding that 
an L1460P mutation in mTOR’s FAT domain, S2215Y mutation in the kinase N-lobe, and 
E2419K in the kinase C-lobe all confer some mTORC1 activity in the absence of PA 
suggests that it is possible for PA-independent mTORC1 activity to result by more than one 
mechanism. Having identified that the activity of S2215Y mTOR is especially independent 
of PA and noting the implications of S2215Y for mTORC1’s structure, I propose that control 
of catalytic cleft access is a major aspect of mTORC1 activation by PA. My investigation 
also produced striking evidence that mTOR autophosphorylation, which is significantly 
hyperactivated by the R2505P mutation, does not necessarily correlate with PA-mediated 
mTORC1 phosphorylation of canonical substrates. Taken together, the experiments detailed 
in this chapter provide insight into the mechanism of mTORC1 activation by PA and carry 
significant therapeutic implications. 
Lastly, in Appendix A, I document several of my preliminary investigations of 
localization-dependent regulation of mTOR signaling. I have observed that both mTOR and 
raptor have a nuclear presence and that the proteins can localize there independently of each 
other. Additionally, I present evidence that nuclear mTORC1 phosphorylates the 
transcriptional repressor, Maf1, in a manner independent of the canonical mTORC1 pathway. 
Finally, I report for the first time that unsaturated PA species appear to recruit mTORC2 to 
detergent-sensitive cellular regions that I believe may be mitochondria-associated 
membranes. 
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CHAPTER I. INTRODUCTION 
 
I.1. mTOR as a Master Regulator of Cellular Homeostasis 
Over the course of a 24-hour period, a single epithelial cell within the human body is 
exposed to a host of synergistic and opposing extracellular signals – many of which signal 
for the reorganization of cellular resources and architecture. These signals range from 
hormonal growth factors to reactive oxygen species and serve to communicate things like 
organismal stress or nutritional status to individual cells. Simultaneously, intracellular 
resources and capacity also fluctuate. In order for cells to respond appropriately to such 
dynamic conditions, each cell must have the ability to sense supply and demand on several 
fronts and maintain a fine balance across the board. Failure to maintain cellular homeostasis 
can lead to a variety of pathologies such as cancer, metabolic disorders, tissue degeneration, 
and neurological disorders. Tight maintenance of homeostasis requires cellular 
communication between a vast array of proteins and signaling molecules, many of which act 
as molecular switches between opposing cellular pathways. One such protein, the 
mammalian target of rapamycin (mTOR), plays an integral role in multiple aspects of cellular 
and organismal physiology. 
Target of rapamycin (TOR), as the name implies, was originally identified, in yeast, 
as the specific target of the bacterial macrolide rapamycin (Heitman et al., 1991). The 
mammalian homolog, mTOR, is a large, 289 kDa protein with Ser/Thr protein kinase 
activity. mTOR is a member of the phosphoinositide 3-kinase related kinase (PIKK) family 
as it contains a FAT (FRAP, ATM, and TRRAP) domain, a PIKK catalytic domain, and a 
carboxy (C) terminal FATC domain (Figure I.1). mTOR’s ability to phosphorylate a range of 
protein substrates and its connection to a multitude of intra- and extra-cellular signaling 
pathways make mTOR a master regulator of cellular processes including transcription, 
translation, lipid metabolism, and cytoskeletal reorganization (Laplante and Sabatini, 2012). 
To do this work, mTOR interacts with many other proteins, and at least one lipid, via its 
distinct domains. 
Just like the other PIKKs, the amino (N) terminal half of mTOR consists of a series of 
HEAT repeats (Huntington, elongation factor 3, protein phosphatase 2A, yeast kinase TOR1) 
that promote protein-protein interactions and are involved in the formation of an mTOR 
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homodimer (Aylett et al., 2016). The C-terminal half of mTOR contains the other PIKK 
hallmarks: FAT, kinase, and FATC domains as well as a unique FRB (FKBP12-rapamycin 
binding) domain sandwiched between the FAT domain and the C-lobe of the kinase domain 
(Aylett et al., 2016) (Figure I.1). The FRB domain is a small (30 Å by 45 Å by 30 Å) 
globular bundle of 4 α-helices (Choi et al. 1996). The first and last helices cross to form a 
hydrophobic pocket that is specifically bound by rapamycin in complex with the 
immunophilin FKBP12 (Banaszynski et al., 2005; Brown et al., 1994; Choi et al., 1996). It is 
both surprising and fortuitous that FKBP12 (FK06/rapamycin binding protein) is a cellular 
receptor for rapamycin – a compound that is not naturally occurring in eukaryotes. While 
neither molecule inhibits mTOR on its own, the heterodimer displays exquisitely specific 
binding to mTOR’s FRB domain and provides a valuable method of mTOR inhibition both in 
vitro and in vivo. In fact, rapamycin has been FDA approved for 4 different clinical 
applications, namely – as an immunosuppressant used during organ transplants, as an anti-
restenosis agent during stent insertion, as an anti-cancer drug, and most recently as the only 
FDA approved treatment for lymphangioleiomyomatosis (The U.S. Food and Drug 
Administration).  
 
I.2. mTOR Interaction with Phosphatidic Acid 
In many cellular contexts, lipid molecules relay information by modulating signaling 
pathways (Spiegel et al., 1996). One well-known lipid second messenger is phosphatidic acid 
(PA). PA is a phospholipid consisting of a glycerol backbone with a phosphate head group 
and two fatty acid tails. The length and degree of saturation of the fatty acid tails can differ, 
resulting in a range of PA species. There is evidence of distinct preferences of PA producing 
enzymes for different precursors (Hodgkin et al., 1998; Pettitt et al., 2001; Zhang et al., 
2012) which, together with specific subcellular localization patterns of the enzymes might 
allow for tailored PA signaling in response to different cellular cues. 
Phospholipase D is one enzyme that generates PA, by catalyzing the hydrolysis of 
phosphatidylcholine. In the absence of stimulants, basal levels of cellular PA are very low 
compared to its precursor lipid, phosphatidylcholine (Buckland and Wilton, 2000). However, 
in response to mitogenic stimulation, PLD catalyzes a significant increase in cellular PA 
(English et al., 1996). This surge of PLD-produced PA molecules is an essential component 
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in the communication of growth factor and amino acid availability to mTOR (Fang et al., 
2003; Sun et al., 2008; Yoon et al., 2011a). In fact, PA binds specifically to the FRB domain 
of mTOR and competes with rapamycin for this binding (Fang et al., 2001). This discovery 
shed light on the role of the FRB domain in mTOR activation and the mechanism of 
inhibition by rapamycin.  Several years later, the exclusive binding of PA was further 
investigated by NMR structural analysis of the FRB domain in complex with PA, which 
confirmed close overlap between PA binding (Veverka et al., 2008) and rapamycin binding 
(Choi et al., 1996) sites. While it is clear that rapamycin works, at least in part, by inhibiting 
PA binding (Fang et al., 2001; Toschi et al., 2009), and that PA binding displaces the 
endogenous inhibitor FKBP38 (Yoon et al., 2011b) questions remain regarding how exactly 
PA activates mTOR kinase activity. My thesis chapters II and III address this question from 
two different angles. 
 
I.3. mTOR Complexes 
mTOR functions within at least two different homodimeric protein complexes. Each 
complex has unique substrates, subcellular localization, and upstream regulators. This allows 
for specific control over a wide range of cellular process in response to a variety of cues. 
Growth factors and amino acids, which are the longest studied mTOR stimulants, activate 
mTORC1 synergistically, whereas mTORC2 responds to growth factors but not amino acids 
(Figure I.2). 
 
I.3.1. mTORC1 Structure 
The first complex that was identified is known as mTOR complex 1 (mTORC1) and 
was originally defined by mTOR’s interaction with the scaffold protein raptor (regulatory 
associated protein of mTOR). The entire amino terminus of mTOR, consisting of a series of 
HEAT repeats, is required for interaction with multiple sites spanning the raptor protein (Kim 
et al., 2002). This interaction is important for mTORC1 kinase activity, as raptor stabilizes 
mTORC1 and presents substrates to promote their phosphorylation by the kinase (Hara et al., 
2002). This function of raptor is mediated by its binding to the TOS (TOR signaling) motif of 
substrates and appears to be required for the phosphorylation of all mTORC1 substrates 
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(Beugnet et al., 2003; Choi et al., 2003; Eguchi et al., 2006; Hara et al., 2002; Lee et al., 
2008; Nojima et al., 2003; Schalm and Blenis, 2002; Schalm et al., 2003). 
Further biochemical studies revealed that the mTOR-raptor complex associates with 
several additional regulatory proteins. The mammalian ortholog of the yeast LST8 protein 
(mLST8) binds the catalytic domain of mTOR and is important for mTOR activity, though 
the mechanistic details remain unclear. mLST8 was shown to increase mTOR interaction 
with raptor (Kim et al., 2003) and likely acts by other mechanisms as well. The proteins 
PRAS40 and FKBP38 also interact with mTORC1, functioning as inhibitors (Bai et al., 2007; 
Wang et al., 2007). A third endogenous inhibitor, DEPTOR (Dishevelled, Egl-10, Pleckstrin 
domain containing protein associated with mTOR), is common to both mTORC1 and a 
second mTOR complex, mTORC2 (Peterson et al., 2009). DEPTOR has been the subject of 
significant research efforts over the last several years and has functional implications in 
cancer and metabolic disorders (Bruneau et al., 2013; Caron et al., 2016; Chen et al., 2015; 
Das et al., 2014; Duan et al., 2011; Gao et al., 2011; González-Terán et al., 2016; Yoon et al., 
2015; Zhao et al., 2011). 
In addition to interacting with regulatory proteins, mTOR also oligomerizes. The first 
evidence that the mTOR-raptor complex exists as a dimer was provided by way of genetic 
and biochemical studies in yeast, drosophila, and mammalian cells (Takahara et al., 2006; 
Urano et al., 2007; Wang et al., 2006; Zhang et al., 2006). Since then, the biochemistry, 
stoichiometry, assembly, and structure of the mTORC1 homodimer has been confirmed by 
several elegant structural and single molecule studies (Aylett et al., 2016; Jain et al., 2014; 
Yang et al., 2013; Yip et al., 2010). While dimerization does change the confirmation of the 
FAT domains within mTORC1, it does not appear to affect the conformation of the kinase 
domains themselves (Aylett et al., 2016). Together, these structural analyses provide 
significant insight into the steric hindrance and conformational changes that likely regulate 
mTOR kinase activity. Visualizing the orientation of mTOR’s FAT domain and catalytic 
cleft relative to mLST8 and the FRB domain with or without FKBP12-rapamycin indicates 
that substrate access to the catalytic cleft is a major determinant of mTOR catalytic activity 
(Aylett et al., 2016) (See Figure I.3 for an mTORC1 structure adapted from that published by 
Aylett et al.).  
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I.3.2. mTORC1 Signaling 
The best-characterized function of mTORC1 is the control of cell growth via the 
regulation of protein translation. When activated by mitogenic stimuli, mTORC1 
phosphorylates S6K1 (ribosomal protein S6 kinase 1), which promotes protein translation. 
Under the same conditions, mTORC1 also phosphorylates the translation repressor 4EBP1 
(eukaryotic translation initiation factor 4E binding protein 1), which results in the 
dissociation of eukaryotic translation initiation factor 4E from 4EBP1 and promotes protein 
translation (Ma and Blenis, 2009). 
As a master regulator of biosynthesis, mTORC1 also upregulates the transcription of 
gene products in several pathways. By specifically phosphorylating the transcription factor 
STAT3 (Kim et al., 2009; Yokogami et al., 2000), mTORC1 increases expression of genes 
involved in cytokine and growth factor signaling. Similarly, mTORC1 influences the 
transcription of energy and lipid metabolism genes via positive regulation of HIF1α 
(Brugarolas et al., 2003; Düvel et al., 2010; Hudson et al., 2002; Laughner et al., 2001) and 
SREBP1 (Düvel et al., 2010; Li et al., 2010; Porstmann et al., 2008; Wang et al., 2011), 
though these transcription factors may not be direct targets of mTORC1. As is the case with 
4EBP1, phosphorylation by mTORC1 sometimes results in inhibition, rather than activation. 
This is true of mTORC1 phosphorylation of the RNA pol III repressor Maf1 and of the 
phosphorylation of ULK1, ATG13, and DAP1 that inhibits autophagy. 
mTORC1 also participates in more complex feed-back/feed-forward mechanisms 
wherein it phosphorylates raptor (Wang et al., 2009) and the inhibitors PRAS40 and 
DEPTOR in order to increase its kinase activity and phosphorylates Grb10 to downregulate 
growth factor signaling through receptor tyrosine kinases (Laplante and Sabatini, 2012). 
Intriguingly, while most mTORC1 substrates were identified based on their susceptibility to 
inhibition by rapamycin, the substrates exhibit a range of rapamycin susceptibility that 
correlates with the sequence of their phosphorylation sites and their sensitivity to cellular 
signals (Kang et al., 2013). Thus, it appears that while all mTORC1 substrates are recruited 
by raptor, they are not necessarily recruited or presented equally. Structural analysis revealed 
that the FKBP12-rapamycin complex is positioned between raptor and mTOR’s catalytic 
cleft, further indicating that differences in substrate interaction with or presentation by raptor 
might underpin their rapamycin sensitivities (Aylett et al., 2016).  
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I.3.3. mTORC2 Structure 
Two years after the identification of mTORC1, a second, raptor-independent, 
complex was discovered (Jacinto et al., 2004; Sarbassov et al., 2004). Now called mTORC2, 
this complex is defined by the interaction between mTOR and a protein deemed rapamycin-
insensitive companion of mTOR (rictor). As the name implies, the rictor-mTOR complex 
was originally identified to be resistant to inhibition by rapamycin. More recently it became 
clear that mTORC2 is insensitive to acute rapamycin treatment, but the complex assembly 
and resulting activity is blocked by prolonged exposure to rapamycin (Sarbassov et al., 
2006). 
In addition to mTOR, mLST8, and DEPTOR, which are common to Complexes 1 and 
2, mTORC2 contains the positive regulators mSin1 and protor (protein observed with rictor) 
(Frias et al., 2006; Lu et al., 2011; Pearce et al., 2007, 2011; Thedieck et al., 2007; Woo et 
al., 2007), and is inhibited by interaction with XPLN (exchange factor found in platelets, 
leukemic, and neuronal tissues) (Khanna et al., 2013). Interestingly, when Frias et al. 
identified mSin1 as a component of mTORC2, they actually found three different isoforms of 
mSin1 that assemble and activate three distinct mTORC2s in response to different signals 
(Frias et al., 2006). The oligomeric state of the mTORC2 complex has been debated, but a 
recent investigation with single molecule resolution suggests that mTORC2 exists in cells as 
a dimer, similar to mTORC1 (Jain et al., 2014). 
 
1.3.4. mTORC2 Signaling 
Compared to what is known about mTORC1 signaling, significantly less is 
understood about mTORC2 due, in part, to the delayed identification of a chemical inhibitor 
able to acutely inhibit mTORC2 signaling. However, there is a large body of evidence 
linking mTORC2 activity to cellular differentiation, survival, and cytoskeletal reorganization. 
mTORC2 activity in each of these processes has been linked to its phosphorylation of 
specific substrates. Akt, PKC, and SGK1 are all AGC family kinases and confirmed 
substrates of mTORC2 (Oh and Jacinto, 2011). The phosphorylation status of Akt is 
correlated with cancer progression, and the regulation of Akt and PKC have been found to 
play roles in cell migration and metabolism (Oh and Jacinto, 2011). SGK1 may be involved 
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in cancer growth and progression, as well as fat metabolism, reproduction, and lifespan 
(Alessi et al., 2009). 
Complicating the elucidation of upstream regulators of mTORC2 is the fact that 
mTORC2 signaling is coupled to that of mTORC1 via negative regulation by mTORC1 (Ge 
et al., 2011; Peterson et al., 2009). mTORC2 activation can occur as a result of insulin 
signaling to PI3K and involves association with ribosomes (Zinzalla et al., 2011). 
Interestingly, ribosome biogenesis and translational activity is influenced by mTORC1 (Ma 
and Blenis, 2009). There is evidence that the Rho GTPase pathway involving Rac1 and Rex1 
regulates mTORC2 activity and connects both mTOR complexes in the control of cell 
growth (Hernández-Negrete et al., 2007; Saci et al., 2011). 
 
I.4. Regulation of mTORC1 Signaling 
 
I.4.1. mTORC1 Inhibition 
As a master regulator, the essence of mTOR’s role is to respond to changing stimuli 
by up- or down-regulating a variety of cellular processes appropriately. Structural analyses of 
C-terminal and full length mTOR revealed that the kinase actually exists in an intrinsically 
active conformation (Aylett et al., 2016; Yang et al., 2013). This atypical intrinsic activity 
necessitates negative regulatory mechanisms to control mTOR’s response to cellular cues. 
Under conditions which preclude cell growth or proliferation, the levels of PRAS40 and 
DEPTOR bound to mTORC1 rise, resulting in inhibition of mTORC1 (Peterson et al., 2009; 
Sancak et al., 2007; Wang et al., 2007).  
Though it is not an endogenous inhibitor, the FKBP12-rapamycin complex is well 
studied and illuminates at least one mechanism of mTORC1 inhibition. The unprecedented 
resolution achieved in the most recent structural analysis of mTORC1 revealed that the width 
of the catalytic cleft is reduced to a mere ~10 Å when the FKBP12-rapamycin complex is 
bound to mTORC1(Aylett et al., 2016). This new perspective suggests that endogenous 
inhibitors like DEPTOR or PRAS40 may well function simply by restricting substrate access 
to the catalytic cleft. Interestingly, raptor is partially responsible for restricting the catalytic 
cleft to ~20 Å even in the absence of inhibitors, indicating that this scaffold protein functions 
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not only in recruiting substrates via their TOS motifs but also in preventing promiscuous 
protein phosphorylation (Aylett et al., 2016). 
 
I.4.2. mTORC1 Activation by Amino Acids 
Many of the cellular responses controlled by mTOR require increased protein 
production – either within a particular functional class of proteins (Sampath et al., 2008) or 
on a global level (Fingar and Blenis, 2004; Ma and Blenis, 2009). Protein translation is an 
energetically and economically large commitment (Shimizu et al., 2001) and is not beneficial 
to initiate in the absence of appropriate resources like amino acids. As such, it is important 
that mTOR’s master regulatory activity is modulated in response to amino acid availability. 
So important, in fact, that mTOR activation in response to growth factors is dependent on 
amino acids (Fang et al., 2001; Sun et al., 2008). Several distinct amino acid sensing 
mechanisms have been identified in the last decade, all of which funnel into one of two 
parallel regulatory axes to remove mTORC1 inhibitors and promote substrate 
phosphorylation. 
The discovery that PA binding to the FRB domain of mTOR is required for mTOR 
activation (Fang et al., 2001) prompted investigation into the relationship between mTOR 
and PLD1. Inhibition of PLD1 activity with 1-butanol and, in later studies, the more specific 
inhibitor FIPI or RNA-mediated protein knockdown revealed that PA produced by PLD1 
does indeed regulate mTORC1 (Fang et al., 2001, 2003; Kam and Exton, 2004). Subsequent 
studies confirmed that PLD1 lies upstream of mTORC1 in multiple cellular processes (Fang 
et al., 2003; Hong-Brown et al., 2013; Hornberger et al., 2006; Sun et al., 2008; Yoon et al., 
2011a) and that PLD1’s effect on mTOR is mediated by PA (Foster et al., 2014; Sun et al., 
2008; Yoon et al., 2011a, 2011b). 
The requirement for both PA and amino acids in mitogenic stimulation of mTORC1 
prompted our group to investigate the relationship between the two. PLD1 activity is 
significantly inhibited by amino acid withdrawal, restored by the re-addition of amino acids, 
and is essential for amino acid activation of mTORC1 (Sun et al., 2008; Yoon et al., 2011a). 
The study by Yoon et al. revealed that the Class III PI-3-kinase Vps34 (vacuolar protein 
sorting 34), in response to amino acids, produces phosphoinositol 3-phosphate which recruits 
PLD1 to the lysosomal surface via its Phox homology domain. This functional relationship 
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between Vps34 and PLD1 is essential for PLD1 activation, lysosomal translocation, and 
activation of mTORC1 in response to amino acids.  
Notably, the study by Yoon et al. contributed further evidence and an additional 
dimension to a model that had just recently emerged – namely that mTORC1 itself must be 
recruited to the lysosomal surface in order to be activated by amino acids (Sancak et al., 
2010). The study by Sancak et al. revealed a different amino acid sensing mechanism 
responsible for activating mTORC1 at the lysosome. This parallel pathway, which is defined 
by Rag GTPases that bind raptor and recruit mTORC1 to the lysosome in the presence of 
amino acids, may explain why PA, though required, is not sufficient to activate mTORC1. 
On its own, PA stimulation does not activate mTORC1 in the absence of amino acids, 
indicating that activation by the PLD1 axis requires another amino acid-sensitive permissive 
signal – perhaps from the Rag axis. 
 
I.4.3. mTORC1 Activation by Growth Factors 
While amino acids are sufficient to stimulate mild mTORC1 activity, maximal kinase 
activity requires additional cues from growth factors. It is well established that the small 
GTPase Rheb (Ras homologue enriched in brain) activates mTORC1 (Long et al., 2005; Tee 
and Blenis, 2005; Tee et al., 2005). In fact, constitutively active Rheb is sufficient to 
stimulate oncogenic cell growth that correlates with increased mTOR activity (Ghosh et al., 
2015; Jiang and Vogt, 2008). The molecular mechanism underpinning this activation remains 
unclear more than a decade after Rheb was found to be upstream of mTOR. It is evident, 
however, that only GTP-bound Rheb activates mTORC1 (Long et al., 2005) and that this 
activation involves direct interaction between Rheb and mTORC1 (Tee et al., 2005). In the 
absence of growth factors Rheb is converted to a GDP-bound state as a result of the GEF 
activity of a protein complex consisting of tuberous sclerosis proteins 1 and 2 (TSC1/2). The 
activation of Class I PI3K signaling in response to growth factors initiates a signaling 
cascade that results in the repression of TSC1/2 and thereby promotes activation of mTORC1 
by Rheb. Previous work from this laboratory has clearly demonstrated that PLD, which is 
activated by mitogens in addition to amino acids, is also involved in mTOR activation by 
Rheb (Fang et al., 2003; Sun et al., 2008). 
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I.4.4. Hyperactivating mTOR Mutations 
Despite the requirement for Rheb in canonical mTORC1 activation, several 
hyperactivating mTOR mutations were reported to confer Rheb-independence in fission yeast 
and mitogen-independent growth in mammalian cells (Urano et al., 2007). Since Rheb 
interacts with mTOR and also interacts with PLD1 in a GTP-dependent manner, it may be 
that Rheb promotes mTORC1 activation by bringing PLD1 and PA into appropriate 
proximity to the kinase. Additionally, Rheb interaction with mTOR could change the 
conformation of mTOR to promote interaction with PLD1 or PA. In either case, mutations in 
mTOR that confer Rheb resistance could do so by promoting mTOR interaction with PLD1 
or PA. In the absence of nutrients, PLD1 normally dissociates from the lysosome (Yoon et 
al., 2011a). Notably, Rheb-independent hyperactive mTOR remains sensitive to rapamycin 
(Ghosh et al., 2015; Urano et al., 2007). This is consistent with Rheb being upstream of 
mTOR activation by PLD1, since rapamycin competes with PA for binding to the FRB 
domain and likely inhibits mTORC1 by preventing PA binding (Fang et al., 2001). 
Additional mechanisms of mTORC1 inhibition by rapamycin that may occur simultaneous 
with, but independent of, PA binding are steric restriction of substrate access to mTOR’s 
catalytic cleft by rapamycin-FKBP12 (Aylett et al., 2016; Yang et al., 2013), and reduced 
substrate binding to the FRB domain (Yang et al., 2013). 
Hyperactivating mutations have actually been reported to span the breadth of the C-
terminal half of mTOR. Mutations within the FRB domain and ATP binding pocket of 
mTOR confer caffeine resistance to TORC1 and were some of the first functional mutations 
reported for the TOR protein (Reinke et al., 2006). Then, just one year after the Rheb-
independent mutants were reported by Urano et al., several other mTOR mutations were 
identified that conferred amino acid resistance to mTOR signaling (Ohne et al., 2008) and 
two distinct hyperactivating mTOR mutations were discovered in a human cancer genome 
database (Sato et al., 2010). Since then, database mining has revealed a slew of 
hyperactivating mTOR mutations present in human cancers (Grabiner et al., 2014; Jahn et al., 
2016). Notably, all of these hyperactive mTOR proteins remain sensitive to rapamycin. This 
is intriguing as it suggests that in each case the kinase activity is being activated by a 
mechanism at least partially independent of the mode of rapamycin action. Additionally, as 
Grabiner et al. discovered, the dependence of particular cancers on rapamycin-sensitive, 
	 11	
hyperactive mTOR increases the susceptibility of such cancers to rapamycin (Grabiner et al., 
2014). To date, there are relatively few indications as to the molecular mechanisms by which 
these reported mutations confer hyperactivity. As the hyperactivity is defined by resistance to 
amino acid withdrawal, it is likely that at least some of these mutants are actually 
independent of PA signaling to mTORC1. Indeed, one mutant has already been shown to 
maintain activity in spite of PLD inhibition by 1-butanol (Sato et al., 2010). In chapter III I 
further probe the possibility and molecular mechanism of PA-independence conferred by 
hyperactivating mTOR mutations. 
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I.5. Figures 
 
 
Figure I.1. Domains of the mTOR protein. Noteworthy interactions occur within the 
following domains: HEAT repeats interact with raptor; FAT interacts with DEPTOR; FRB 
interacts with the FKBP12-rapamycin complex and with phosphatidic acid; LBE is required 
for interaction with mLST8. 
	 13	
  
Figure I.2. mTOR complexes. mTORC1 and mTORC2 are depicted as homodimers 
composed of common (mTOR, mLST8) and unique (raptor or rictor, mSin1, and protor) 
elements. Cellular cues are communicated to the mTOR complexes by several upstream 
regulators, leading to the phosphorylation and control of specific downstream substrates. 
	 14	
 
 
Figure I.3. mTORC1 Structure. mTORC1 exists as a symmetrical homodimer. Shown is 
one monomer (colored) and its interface with the other monomer (grey). Color assignements 
correspond to the mTOR domain diagram in Figure I.1. The HEAT containing horn and 
bridge domains of mTOR (red and salmon) transition into the FAT domain (blue), which 
wraps around the kinase domain (purple) and turns up as the FRB domain (cyan). The C-
terminus of the FRB domain connects to the kinase domain (purple) with forms the majority 
of the architecture of the catalytic cleft. The LBE domain (orange) binds mLST8 (gold). 
Rapamycin in complex with FKBP12 (pink) binds to the FRB domain, restricting access to 
the catalytic cleft. Raptor (olive), the defining component of mTORC1, comes within close 
proximity of the FRB domain and the catalytic cleft. This image was created with The 
PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC., using the mTORC1 
structural file (PDBID: 5FLC) deposited in the RCSB Protein Data Bank (Aylett et al. 2016). 
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CHAPTER II. RAPID MITOGENIC REGULATION OF THE MTORC1 
INHIBITOR, DEPTOR, BY PHOSPHATIDIC ACID1 
 
II.1. Introduction  
Mammalian target of rapamycin (mTOR) is a Ser/Thr kinase that responds to a 
variety of intra- and extra-cellular signals such as amino acids and mitogens in order to 
coordinate a multitude of cellular processes with the appropriate resources and demand. As a 
master regulator, mTOR nucleates two biochemically and functionally distinct complexes, 
namely mTORC1 and mTORC2, which lie at the center of an extensive signaling network 
(Laplante and Sabatini, 2012). In its active form, mTORC1 stimulates protein synthesis and 
cell growth through the phosphorylation of the ribosomal S6 kinase (S6K1) and other 
substrates (Ma and Blenis, 2009). Catalytically active mTORC2, on the other hand, 
phosphorylates a different set of substrates, with Akt being the best characterized (Laplante 
and Sabatini, 2012; Oh and Jacinto, 2011). Downstream signaling of both mTOR complexes 
is activated in response to mitogens. In the case of mTORC1, this process is dependent on 
amino acids, which trigger the recruitment of mTORC1 to lysosomal membranes through the 
Rag small GTPases (Sancak et al., 2008, 2010), where it is activated by another small 
GTPase, Rheb (Menon et al., 2014), and phospholipase D1 (PLD1) (Yoon et al., 2011a).  
PLD1 and PLD2 catalyze the hydrolysis of phosphatidylcholine (PC) to phosphatidic 
acid (PA). Both PLD enzymes preferentially hydrolyze mono- or di-unsaturated PC, 
generating PA species with one or two degrees of unsaturation (Pettitt et al., 2001). 
Phosphatidic acid produced by PLD serves, primarily, as a second messenger to regulate a 
range of signaling proteins (Jenkins and Frohman, 2005). Previously, we identified that 
monounsaturated 16:0-18:1 PA binds with high affinity to the FKBP12 rapamycin binding 
(FRB) domain of mTOR and that this interaction is in direct competition with the mTOR-
specific inhibitor, rapamycin (Fang et al., 2001). Furthermore, we have shown that PLD1 and 
PA are critical mediators of mTORC1 activation by mitogens as well as amino acid signals 
(Fang et al., 2001, 2003; Sun et al., 2008; Yoon et al., 2011a), and that PA binding directly 																																																								1	Chapter II has been published as: Yoon, M.-S., Rosenberger, C.L., et al. (2015) Rapid Mitogenic Regulation 
of the mTORC1 inhibitor, DEPTOR, by Phosphatidic Acid. Molecular Cell. 58:549-556. Copyright (2015) 
Elsevier Inc. Reprinted with permission. 
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stimulates mTORC1 kinase activity (Yoon et al., 2011b). Such regulation of mTOR 
interactions and, thereby, mTOR activity is crucial for maintaining tight control of cell 
growth and proliferation. 
Indeed, while mutations in mTOR itself have only recently been functionally 
correlated with disease, dysregulation of the mTOR signaling pathway has been suggested to 
be a common contributor in cancer (Guertin and Sabatini, 2007). DEPTOR is one such 
protein that normally binds and inhibits both mTOR complexes but, when overexpressed, 
alleviates mTORC1 inhibition of mTORC2 signaling, and thereby promotes cancer cell 
survival (Peterson et al., 2009). In the absence of mitogens, DEPTOR mRNA and protein 
levels rise, giving way to increased interaction with and inhibition of both mTOR complexes 
(Peterson et al., 2009). Following the addition of mitogens, DEPTOR is phosphorylated by 
mTOR, triggering its ubiquitination and subsequent degradation over the course of several 
hours (Duan et al., 2011; Gao et al., 2011; Peterson et al., 2009; Zhao et al., 2011). While this 
gradual degradation of DEPTOR may underlie prolonged or basal mTOR activation, it 
cannot explain how acute stimulation of mTOR triggers maximal signaling activity long 
before DEPTOR protein levels are affected. Herein, we report that PA produced by PLD 
specifically binds to mTOR and displaces DEPTOR, revealing, for the first time, a 
mechanism of acute mTOR regulation involving DEPTOR. 
 
II.2. Materials and Methods 
 
II.2.1. Antibodies and Other Reagents 
All antibodies used in this study were obtained from the following commercial 
sources: anti-Flag M2 from Sigma-Aldrich, anti-raptor and -rictor for immunoprecipitation 
(A300-553A and A300-458A, respectively) from Bethyl Laboratory, Inc., anti-DEPTOR 
(NBP1-49674) from Novus, anti-tubulin and anti-LAMP1 (ab25630) from Abcam, Alexa 
Fluor 594 anti-mouse from Life Technologies (A11020), all other secondary antibodies from 
Jackson ImmunoResearch, and all other antibodies from Cell Signaling. Glutathione 
Sepharose was from GE Healthcare. Protein G-agarose was from Millipore. All lipids were 
purchased from Avanti Lipids. All other reagents were purchased from Sigma-Aldrich. 
 
	 25	
II.2.2. Plasmids 
Flag-mTOR plasmid was described previously (Vilella-Bach et al., 1999). Human 
DEPTOR cDNA constructs were obtained from Addgene: plasmid 21334 (pRK5-Flag-
DEPTOR) and plasmid 21702 (pRK5-Flag-DEPTOR, 13xS/TàA or 13A) (Peterson et al., 
2009). The PASS biosensor for PA was a generous gift from Dr. Guangwei Du (Zhang et al., 
2014). 
 
II.2.3. Cell Culture 
HEK293 and HeLa cells were maintained in DMEM containing 10% fetal bovine 
serum (FBS) at 37 °C with 5.5%. C2C12 cells were cultured similarly as above but with 
7.5% CO2. HEK293 cells stably expressing Flag-mTOR, Flag-DEPTOR-WT, Flag-
DEPTOR-13A, FlagmTOR(RR), or Flag-mTOR(RR/KI) were selected with 1 mg/mL G418. 
Swiss 3T3 cells were grown in DMEM containing 10% calf serum at 37°C with 5.5% CO2. 
Transfections were performed with Polyfect (Qiagen) following the manufacturers’ 
recommendations. Serum starvation was achieved by incubating cells in serum-free DMEM 
overnight, and 10% FBS was used for serum stimulation. 
 
II.2.4. Cell lysis, Immunoprecipitation (IP) and Western Blotting 
For IP, cells were lysed in ice-cold lysis buffer (40 mM HEPES, pH7.4, 120 mM 
NaCl, 10 mM sodium pyrophosphate, 50 mM NaF, 2 mM EDTA, 1x protease inhibitor 
cocktail (PIC) (Sigma-Aldrich), and 0.05% saponin). To make lysates for western blotting 
only, cells were lysed in 20 mM Tris-HCl at pH7.5, 0.1 mM Na3VO4, 25 mM NaF, 25 mM 
glycerophosphate, 2mM EGTA, 0.3% Triton X-100. Upon cell lysis, the lysate supernatant 
was collected after centrifugation at 10,000g for 10 min, and subjected to IP at 4 °C with 
various antibodies and protein G Sepharose. Lysates and IP products were mixed with SDS 
sample buffer containing 5% final concentration of 2-mercaptoethanol. C2C12 cells were 
lysed directly in SDS sample buffer with 5% 2-mercaptoethanol and subjected to brief 
sonication to shear genomic DNA. All samples were boiled for 5 min and proteins were 
resolved on SDS-PAGE and transferred onto PVDF membranes (Millipore). Antibody 
incubations were performed following the manufacturers’ recommendations. Detection of 
horseradish peroxidase-conjugated secondary antibodies was performed with 
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chemiluminescence solution (100 mM Tris-HCl, 0.009% H2O2, 225 µM coumaric acid, 1.25 
mM luminol). Images were developed on x-ray films. Quantification of band intensities was 
performed by densitometry of film images using the Image J software. 
 
II.2.5. Immunofluorescence imaging 
HEK293 cells cultured on poly-L-lysine-coated glass coverslips were transfected and 
treated as indicated in the legend of Figure II.4, followed by fixation in 3.7% 
paraformaldehyde and permeabilization with 0.1% Triton X-100. Incubation with anti-
LAMP1 antibody was performed in 3% BSA/PBS at room temperature for 2 hrs, followed by 
incubation with Alexa 594-antimouse antibody in 3% BSA/PBS for 30 min at room 
temperature. A personal deconvolution microscope system (DeltaVision; Applied Precision) 
was used with a 60x NA 1.4 lens to analyze the fluorescence images as previously described 
(Yoon et al., 2011a). 
 
II.2.6. Lipid Vesicle Preparation 
All lipids were purchased from Avanti Polar Lipids, Inc. in chloroform. For cell 
stimulation and in vitro kinase assay, dioctyl-phosphatidic acid (C8PA), various forms of 
longchain PA, and PC vesicles were prepared as previously described (Yoon et al., 2011b) by 
water bath sonication, at a final concentration of 3 mM. For in vitro FRB-lipid binding assay, 
SUVs were prepared by microprobe sonication as described previously (Fang et al., 2001). In 
this case, each vesicle preparation contained 16.67 mg of lipid (10% PA and 90% PC or 
100% PC) in a total volume of 1 mL. 
 
II.2.7. In Vitro mTORC1 Kinase Assay 
mTORC1 was immunoprecipitated and the kinase assays were performed as 
previously described (Yoon et al., 2011b), with 100 ng GST-S6K1 as the substrate. Where 
applicable, PA or PC vesicles were added to the washed immunocomplexes 15 minutes 
before initiation of the kinase assay by the addition of ATP. 
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II.2.8. FRB Binding Assay 
The FRB protein was expressed and purified as we previously reported (Vilella-Bach 
et al., 1999). Microprobe sonication-generated SUVs containing PA and PC (1:9) or PC 
alone were tested for FRB binding, following procedures we previously described (Fang et 
al., 2001). Briefly, SUVs were incubated with purified FRB at room temperature for 30 min, 
and then analyzed by size-exclusion on a Sephracryl-300 column. Elutions were analyzed on 
15% SDS gels by silver-staining. 
 
II.2.9. PLD Assay 
PLD activity was determined as previously described, by measuring 
[3H]phosphatidylbutanol (PBt) produced in [3H]oleic acid-labeled cells via PLD-catalyzed 
transphosphatidylation (Fang et al., 2003; Mee-Sup Yoon, 2006) 
 
II.2.10. Lentivirus-mediated RNAi 
Lentiviral shRNA plasmids used in this study were in the pLKO.1puro vector and 
obtained from Sigma-Aldrich (Mission® shRNA). The human PLD1 shRNA 
(TRCN0000001011) and the negative control shRNA (scrambled hairpin sequence) were 
previously described (Yoon et al., 2011a). The human DEPTOR shRNA 
(TRCN0000168363) was also reported (Peterson et al., 2009). Viral packaging, infection, 
and puromycin selection of infected cells were performed as previously described (Yoon et 
al., 2011a). 
 
II.2.11. mTOR Pulldown and Mass Spectrometry 
HEK293 cells stably expressing Flag-mTOR were grown to confluency in 15-cm 
plates and serum starved overnight. Cells on half of the plates were exposed to di-8:0 PA for 
30 min, and then lysed. Lysates from each set of 8 plates were combined as one sample and 
subjected to anti-Flag IP. As a background control, anti-Flag IP was also performed with 
lysates of serum starved plain HEK293 cells. For each sample, Flag bead-associated proteins 
were washed five times with IP lysis buffer (without PIC) and five times with PBS, and then 
subjected to trypsin digest. The resulting peptides were loaded onto a PLRP-S trap column 
and resolved by PLRP-S analytical column using Eksigent 2D nano-liquid chromatography 
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system. The samples after nanoLC separation were electrosprayed into a custom hybrid 
linear-ion-trap Fourier-transform ion cyclotron resonance mass spectrometer (11-Tesla LTQ-
FTUltra mass spectrometer, Thermo Fisher Scientific) as previously described (Wu et al., 
2012). Full scans were collected at 25,000 resolution; a data-dependent top-3 method was 
used for tandem mass spectrometry in FT-ICR cell at 12,500 resolution. The MS data were 
collected as a .raw file, processed in ProSightPC 2.0 SP1 software (Thermo Fisher 
Scientific), and searched against a human trypsin database on a multi-core cluster in absolute 
search mode (previously described, Wu et al., 2012). Specific mTOR-interacting proteins 
were identified by eliminating proteins that also appeared in the background IP. mTOR-
interacting proteins were then examined in Qual Browser for relative abundance comparison 
between starved and PA-treated samples.  
 
II.2.12. Statistical Analysis 
All quantitative data are presented as mean ± standard deviation (SD) of at least three 
independent experiments. Whenever necessary, statistical significance of the data was 
analyzed by performing a one-sample or paired Student’s t test as indicated in figure legends. 
*P ≤ 0.05. **P ≤ 0.01. 
 
II.3. Results 
 
II.3.1. Acute Mitogenic Stimulation Disrupts DEPTOR-mTORC1 Interaction 
Aware that mitogenic stimulation triggers rapid activation of mTORC1 and 
mTORC2, we wondered if any effect on the endogenous inhibitor, DEPTOR, could be 
detected within the same time frame. As shown in Figure II.1A, phosphorylation of the 
mTORC1 substrates S6K1 and 4EBP1 was robustly induced by 30 min stimulation with 
phorbol 12 myristate 13-acetate (PMA), serum, or insulin. As expected, mTORC1 and 
mTORC2 isolated from serum-starved cells by raptor and rictor immunoprecipitation, 
respectively, were bound by DEPTOR. Intriguingly, all three stimuli reduced the amount of 
DEPTOR associated with mTORC1, but not mTORC2, within the same time window as 
mTORC1 substrate phosphorylation (Figure II.1A). 
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Extending our analysis to C2C12 (Figure II.1B) and Swiss 3T3 cells (Figure II.1C) 
revealed that mitogen-stimulated DEPTOR displacement from mTORC1 is conserved across 
cell types. In addition, we found that lysophosphatidic acid (LPA), which activates PLD1 and 
thereby mTORC1 (Kam and Exton, 2004), also induced DEPTOR dissociation from 
mTORC1 in Swiss 3T3 cells (Figure II.2). We observed that stimulation with amino acids, 
another mTORC1 stimulus, also caused DEPTOR displacement (Figure II.2C), though this 
effect was not seen in the absence of mitogens (data not shown). Taken together, our results 
suggest, for the first time, that rapid mitogenic activation of mTORC1 may involve 
dissociation of the endogenous inhibitor, DEPTOR. 
 
II.3.2. Mitogen-Induced DEPTOR Dissociation is Mediated by PLD1 and its Product, 
Phosphatidic Acid 
Because all the stimuli shown above to induce DEPTOR dissociation from mTORC1 
are also known to stimulate PLD1, we set out to investigate the possibility of a connection 
between PLD1 and DEPTOR dissociation. Treatment of cells with FIPI (5-Fluoro-2-indolyl 
deschlorohalopemide), an inhibitor of PLD, inhibited mTORC1 activity as confirmed by a 
drastic reduction in PMA-stimulated S6K1 phosphorylation (Figure II.3A). At the same time, 
FIPI blocked PMA-stimulated DEPTOR displacement from mTORC1 (Figure II.3A), and the 
effect of FIPI was dose-dependent (Figure II.4A). Although FIPI at 5 µM inhibited the 
majority of PMA-stimulated PLD activity, an above-basal activity persisted until the cells 
were treated by 30 µM FIPI (Figure II.4B). Importantly, PA production at the lysosome, as 
demonstrated by a PA sensor concentrating at the lysosomal area and colocalizing with the 
lysosomal marker LAMP1, was abolished by 30 µM and not 5 µM FIPI (Figure II.4C). This 
is in full agreement with the requirement of PLD1 lysosomal translocation for mTORC1 
activation (Yoon et al., 2011a). Additionally, FIPI increased the DEPTOR-mTORC1 
association in starved cells (Figure II.3A), which likely reflects a robust FIPI inhibition of 
basal PLD activity otherwise present in starved cells. 
To further validate the specific involvement of PLD1, we delivered a previously 
reported shRNA against PLD1 (Sun et al., 2008) via lentiviral infection of the cells. As 
shown in Figure II.3B, PLD1 knockdown significantly reduced the degree of DEPTOR 
dissociation seen in serum stimulated cells, as compared to cells that received control 
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shRNAs. The less complete blockage of dissociation by RNAi compared to FIPI is likely due 
to the incomplete removal of PLD1 by the knockdown. Collectively, these observations 
strongly suggest that DEPTOR dissociation from mTORC1 is mediated by PLD1. 
Previously, we identified that the PLD1 product PA binds the FRB domain in mTOR 
and showed that PA binding is necessary for mTOR kinase activity and signaling (Fang et 
al., 2001; Yoon et al., 2011b). However, the mechanism of mTOR activation remains 
incompletely understood. In a parallel investigation into the mechanism of mTOR regulation, 
we utilized nano-liquid chromatography (nanoLC) high resolution Fourier-transform mass 
spectrometry (FTMS) to analyze protein interactions with stably expressed Flag-tagged 
mTOR under different conditions. For the purpose of studying exogenous PA effects on 
mTOR in the cell, we routinely used a short-chain PA (di-8:0 PA, or C8PA) in order to 
preclude potential signaling from longchain PA-derived LPA (Yoon et al., 2011b). The 
nanoLC-FTMS analysis revealed that delivery of C8PA to the cells prior to lysis led to 
reduced mTOR interaction with DEPTOR (Figure II.5A) among other proteins (not shown). 
Co-immunoprecipitation experiments confirmed that, indeed, DEPTOR association with 
Flag-mTOR was decreased following treatment of HEK293 cells with PA (Figure II.3C). 
These findings were consistent with our observation that mitogen-stimulated DEPTOR 
displacement is mediated by PLD1, and suggested that the process likely involves PA 
production. 
Next, we examined the effect of PA on the association of endogenous mTOR with 
DEPTOR. Indeed, PA treatment led to a reduced level of DEPTOR in the raptor 
immunoprecipitates (Figure II.3D). It is noteworthy that this effect was specific to PA and 
not recapitulated by rapamycin (Figure II.5B), even though PA and rapamycin compete with 
each other to bind the FRB domain in mTOR (Fang et al., 2001). Surprisingly, the 
association of DEPTOR with mTORC2, as examined by rictor immunoprecipitation, was 
also impaired by PA treatment (Figure II.3D). Nevertheless, whereas the PA-induced 
reduction in DEPTOR incorporation correlated with an increase in mTORC1 activity as 
measured by the phosphorylation of S6K1, mTORC2 activity toward Akt was not stimulated 
by PA treatment (Figure II.3D), as previously described (Yoon et al., 2011b). These data 
suggest that mTORC1 activity, alone, is affected by the reduced DEPTOR binding triggered 
by PA treatment. 
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II.3.3. Phosphatidic Acid Displaces DEPTOR from mTORC1 to Activate Signaling 
Consistent with the reported role of DEPTOR in inhibiting mTORC1, we found that 
DEPTOR overexpression inhibited S6K1 phosphorylation in cells (Figure II.6A). 
Importantly, exogenous PA was sufficient to rescue mTORC1 signaling from the effect of 
DEPTOR overexpression (Figure II.6A) while displacing overexpressed DEPTOR from 
mTORC1 (Figure II.6B). Furthermore, DEPTOR knockdown led to an increase in phospho-
S6K1 in serum-starved HeLa cells as reported (Peterson et al., 2009), but it had no effect on 
phospho-S6K1 stimulated by PA (Figure II.6C) or mitogens (Figure II.7A), validating the 
role of PA in removing DEPTOR inhibition of mTORC1. The capacity of PA to displace 
DEPTOR was confirmed in the same cells (Figure II.7B). 
While these observations are consistent with a model where PA acts by binding to 
mTOR and subsequently dissociating DEPTOR, an equally plausible mechanism could be 
that PA simply activates mTORC1, which leads to phosphorylation (Peterson et al., 2009) 
and subsequent dissociation of DEPTOR. To examine this alternative possibility, we asked if 
phosphorylation by mTOR is required for DEPTOR dissociation. To that end, we utilized a 
nonphosphorylatable mutant of DEPTOR (DEPTOR-13A), which contains alanine 
substitutions at all 13 identified sites phosphorylated by mTOR (Peterson et al., 2009). As 
shown in Figure II.6D, like the wild-type protein, DEPTOR-13A dissociated from mTORC1 
in response to 30-min serum stimulation. To further examine the potential role of mTOR 
activity in DEPTOR dissociation, we took advantage of cells stably expressing a rapamycin-
resistant mTOR in a wild-type (RR) or kinase-inactive (RR/KI) form. In the presence of 
rapamycin, serum-stimulated DEPTOR dissociation continued to occur even in RR/KI cells 
that lacked mTORC1 kinase activity (Figure II.6E). Therefore, DEPTOR displacement from 
mTORC1 is independent of mTORC1 activity and DEPTOR’s mTOR-mediated 
phosphorylation state. 
In response to mitogenic stimulation, PA levels quickly rise and fall back toward 
basal levels within 1 hour of stimulation (Cano et al., 1992; Fang et al., 2001; Fukami and 
Takenawa, 1992). Given this transient PA presence, we wondered if DEPTOR re-associated 
with mTORC1 over time. As shown in Figure II.6F, DEPTOR indeed began to re-associate 
with mTORC1 within 2 hours of stimulation. The re-associated DEPTOR exhibited a diffuse 
resolution by western blotting, most likely reflecting its phosphorylation by mTOR over time 
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as reported. In further support of the functional relevance of DEPTOR displacement, the re-
association was accompanied by a reduction in S6K1 phosphorylation (Figure II.6F), often 
observed within 1-2 hours of mitogenic stimulation in non-cancerous cells (e.g.,(Chung et al., 
1992)). This data is consistent with the idea that as mitogen-induced pools of PA drop to 
basal levels, DEPTOR-mTOR interaction returns and inhibits mTORC1 signaling. 
 
II.3.4. PA Species Containing Unsaturated Acyl Chains Displace DEPTOR and Activate 
mTORC1 
A recent report suggested that not all PA species are created equal but, rather, PA 
produced by different biosynthetic pathways may have distinct signaling capabilities (Zhang 
et al., 2012). Such a possibility prompted us to examine the effect of various PA species on 
mTORC1. PLD primarily generates PA species containing one or two partially unsaturated 
fatty acid chains, including 16:0-18:1, 18:0-18:1, and di-18:1 (Pettitt et al., 2001). On the 
other hand, GPAT1 (glyerol-3-phosphate acyltransferase 1)- and AGPAT2 (1-acyl-glyerol-3-
phosphate acyltransferase 2)-driven PA production generates mainly PA species with 
saturated acyl chains, such as di-16:0 (Zhang et al., 2012). Given the necessity of PLD 
activity for PA-mediated DEPTOR displacement, we reasoned that this mechanism of 
mTORC1 activation might be specific to the class of PA species produced by PLD. Indeed, 
when we assessed the ability of different unsaturated or saturated PA species to stimulate 
mTORC1 activity, we found that all three unsaturated PA species tested (16:0-18:1, 18:0-
18:1, and di-18:1) activated mTORC1 both in cells (Figure II.8A) and in vitro (Figure II.8B), 
while the saturated species (di-16:0 or di-18:0) had no significant effect on mTORC1 
signaling or kinase activity. Furthermore, the ability of the unsaturated PA species to activate 
mTORC1 correlated with their ability to displace DEPTOR from mTORC1 (Figure II.8C). 
These data suggest that the fatty acid chains confer functional specificity to PA, and that PA 
species produced by PLD may have a unique ability to displace DEPTOR from mTORC1 
and activate the kinase. 
Given the importance of PA-mTOR association for mTORC1 activation (Fang et al., 
2001; Yoon et al., 2011b), we reasoned that fatty acid chain unsaturation might influence PA 
affinity for mTOR, thereby constituting a mechanism of species selectivity. To test this 
theory, we performed in vitro FRB-lipid binding assays with vesicles composed of different 
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PA species. As previously described (Fang et al., 2001), purified FRB protein bound to small 
unilamellar vesicles (SUVs) containing 16:0-18:1 PA, as analyzed by size exclusion 
chromatography. As shown in Figure II.8D, 18:0-18:1 and di-18:1 PA vesicles were also 
completely retained by the FRB protein, whereas vesicles containing the saturated di-16:0 
and di-18:0 PA exhibited partial binding to FRB. Because these binding assays were 
performed with identical protein and vesicle concentrations, the binding patterns reflected 
affinity of the various lipids for FRB. The strong interaction between FRB and the 
unsaturated PA species is consistent with the model that PA generated by PLD1 specifically 
interacts with mTOR to activate mTORC1 by displacing the endogenous inhibitor, DEPTOR. 
 
II.4. Discussion 
Identification of the endogenous mTOR inhibitor, DEPTOR, prompted several 
studies into the mechanism and functional consequence of the DEPTOR degradation that 
occurs several hours after mTOR activation (Duan et al., 2011; Gao et al., 2011; Laplante et 
al., 2012; Peterson et al., 2009; Zhao et al., 2011). However, there has been little indication 
of how mTOR rapidly achieves maximal signaling activity long before DEPTOR is 
degraded. Collectively, the results we describe herein indicate that upon mitogenic 
stimulation DEPTOR is rapidly displaced from mTORC1 by PLD-generated PA, allowing 
mTORC1 activation (Figure II.9). To our knowledge, this is the first description of a 
molecular mechanism by which mTORC1 is rapidly and robustly relieved of inhibition by 
DEPTOR and by which mTORC1 regulation is achieved independently of DEPTOR 
phosphorylation, the only event previously known to initiate regulation of DEPTOR. 
Furthermore, we demonstrate that this regulation is dependent on the composition of the PA 
species interacting with mTOR, revealing a preference of mTORC1 for unsaturated PA 
species. Fully in line with the well-known transient kinetics of cellular PA production, we 
have observed re-association of DEPTOR with mTORC1 following prolonged mitogenic 
stimulation, at which time DEPTOR degradation may take over as the primary means of 
removing this inhibitor. 
It is interesting to note that while exogenously supplied PA displaces DEPTOR from 
both mTORC1 and mTORC2, this displacement only has functional consequences for 
mTORC1, as exogenous PA is sufficient to activate mTORC1 but not mTORC2, both in cells 
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and in vitro (Yoon et al., 2011b). This is consistent with the fact that rapamycin, which is a 
competitive inhibitor of PA-mTOR interaction (Fang et al., 2001; Veverka et al., 2008), 
specifically inhibits mTORC1 long before it has any effect on mTORC2 (Sarbassov et al., 
2006). The regulation of mTORC2 may require additional inputs. Perhaps for the same 
reason, mTORC2 appears less sensitive to regulation by DEPTOR, as knockdown of 
DEPTOR is sufficient to activate mTORC1 but not mTORC2, even though overexpression of 
DEPTOR inhibits both complexes (Peterson et al., 2009). 
The reason DEPTOR interaction with mTORC2 is affected by exogenous PA but not 
by mitogenic stimulation may have to do with compartmentalization and subcellular 
concentrations of PA. Both mTORC1 and PLD1 are localized to the lysosome in the 
presence of amino acids (Sancak et al., 2010; Yoon et al., 2011a). mTORC2, on the other 
hand, has primarily been described to reside at the plasma membrane (Partovian et al., 2008) 
and the endoplasmic reticulum (ER) (Boulbés et al., 2011), and therefore is unlikely to 
encounter concentrated pools of PA produced by PLD1. PLD2 also produces PA and is 
broadly localized to the plasma membrane (Zhang and Frohman, 2014), but it has never been 
shown to colocalize with mTORC2. The two may well reside in different membrane 
microdomains. 
In addition to the PLD enzymes, glycerol phosphate acyltransferases (GPATs)/ 
acylglycerolphosphate acyltransferases (AGPATs) and diacylglycerol kinases (DGKs) also 
generate PA. There are many different AGPAT and DGK isoforms; those that are well 
characterized localize predominantly to the ER (Takeuchi and Reue, 2009), plasma 
membrane, and nucleus (Topham and Epand, 2009). Therefore, AGPATs and DGKs are 
unlikely to closely associate with mTORC1 in cells under physiological conditions. When 
overexpressed, AGPAT10 (Tang et al., 2006) and DGKζ (Avila-Flores, 2005) were both 
reported to activate mTORC1, which could be a result of a broadened distribution throughout 
the cell and an increased proximity to mTORC1. In addition to close proximity with 
mTORC1, our results indicate that a propensity to produce unsaturated PA is another 
important dimension of a PA-producing enzyme’s involvement in regulating mTORC1. 
While AGPAT and DGK isoforms are certainly capable of producing unsaturated PA, none 
of them have been found to share the strong preference of the PLD enzymes for generating 
mono- and di-unsaturated PA species (Hollenback, 2005; Pettitt et al., 2001; Sukumaran et 
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al., 2009; Takeuchi and Reue, 2009; Topham and Epand, 2009; Zhang et al., 2012). 
Nevertheless, it has been proposed that PA production by these two pathways could become 
significantly more important for mTOR regulation when production by PLD is compromised 
(Foster et al., 2014). 
The acyl chain requirement for mTOR binding, DEPTOR displacement, and 
activation of mTORC1 described herein indicates the importance of subtle species variation 
within lipid signaling. Together with another recent report that acyl-chain derived specificity 
may functionally differentiate PA from different sources (Zhang et al., 2012), these findings 
contribute an additional degree of sophistication to our understanding of mTOR regulation. 
How the FRB domain of mTOR differentiates between saturated and unsaturated species of 
PA is still unclear. NMR, crystallography, and mutagenesis studies have provided significant 
insights into the structure of the FKBP12-rapamcin/PA binding pocket within FRB (Choi et 
al., 1996; Fang et al., 2001; Leone et al., 2006; Veverka et al., 2008). In the past, emphasis 
has been placed on the interaction between the lipid head group and FRB; significant 
additional insights may be gleaned from future studies addressing the involvement of acyl 
chains in PA-FRB binding. 
 
II.5. Contributions of Co-Workers 
This chapter is the result of collaboration with Dr. Mee Sup Yoon. Dr. Yoon initiated 
this project and made significant contributions to the final results. Data in each figure are the 
result of close collaboration between Dr. Yoon and myself. Nga Truong helped prepare the 
samples for mass spectrometry, and Cong Wu conducted the mass spectrometry analysis. 
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II.6. Figures 
 
                  
 
Figure II.1. Acute mitogenic stimulation disrupts DEPTOR-mTORC1 interaction. 
(A) HEK293 cells were serum starved overnight and stimulated for 30 min with 100 nM 
PMA, 10% serum, or 100 nM insulin. mTORC1 and mTORC2 were isolated by 
immunoprecipitation of raptor and rictor, respectively. Cell lysates and immunoprecipitates 
were analyzed by western blotting. C2C12 cells (B) and Swiss 3T3 cells (C) were serum 
starved overnight and stimulated and analyzed as in (A). Western data shown throughout the 
chapter are representative of three or more independent experiments with similar results. 		 	
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Figure II.2. Disruption of DEPTOR-mTORC1 interaction involves mitogens. (A,B) 
Swiss 3T3 cells were serum starved overnight, and stimulated for 30 min with 10 µM LPA, 
followed by (A) PLD activity assays and (B) raptor IP and western analysis. (C) HEK293 
cells were incubated in amino acids-free medium for 2 hours in the presence of 10% dialyzed 
FBS, followed by stimulation with amino acids- and 10% dialyzed FBS-containing medium 
for 30 min. Raptor IP and cell lysates were analyzed by western blotting. 
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Figure II.3. Mitogen-induced DEPTOR displacement is mediated by PLD1 and PA. (A) 
HEK293 cells were serum starved overnight and stimulated with 200 nM PMA with or 
without 50 µM FIPI for 30 min. Cell lysates and raptor immunoprecipitates were analyzed by 
western blotting. (B) HEK293 cells were infected with a negative control- or PLD1-shRNA 
and selected with puromycin for 3 days, followed by serum starvation overnight, and 10% 
serum stimulation for 30 min. Cell lysates and raptor immunoprecipitates were analyzed as in 
(A). DEPTOR:mTOR ratios were calculated based on band intensities measured by 
densitometry. Data are mean ± SD, with paired t-tests performed as indicated. (C) HEK293 
cells stably expressing Flag-mTOR were serum starved overnight. Where indicated, cells 
were treated for 30 min with 300 µM C8PA vesicles. Flag-IP was performed and analyzed by 
western blotting. (D) mTORC1 and mTORC2 were isolated as raptor and rictor 
immunoprecipitates, respectively, from cells starved or stimulated and analyzed as in (B). 
Data are mean ± SD, analyzed by one-sample t-tests.  
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Figure II.4. PLD activity is necessary for mitogenic disruption of DEPTOR-mTORC1 
interaction. (A) HEK293 cells were serum starved overnight, then stimulated with 200 nM 
PMA in the presence of increasing concentrations of FIPI for 30 min. Cell lysates and raptor 
IP were analyzed by western blotting. (B) Cells treated as above were subjected to PLD 
assay. Data shown are mean ± standard deviation of triplicates. *P ≤ 0.05 when compared to 
“no PMA no FIPI” by t-test. (C) Cells were transfected with a GFP PA biosensor for 24 hrs, 
serum starved, and then stimulated with 200 nM PMA in the presence of 0, 5, or 30 µM FIPI 
for 30 min, followed by immunostaining with an anti-LAMP1 antibody. The merged images 
were pseudocolored with green for GFP and red for LAMP1. Scale bar: 5 µm. Enlarged (8x) 
images of the merges are also shown. Results shown are representative of 3 independent 
experiments with similar outcome. 
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Figure II.5. PA specifically disrupts DEPTOR-mTORC1 interaction. (A) HEK293 cells 
stably expressing Flag-mTOR were serum starved overnight and stimulated for 30 min with 
300 µM C8PA vesicles. Flag-mTOR and associated proteins were isolated by 
Flag-IP and subjected to trypsin digest. Resulting peptides were analyzed by mass 
spectrometry. Shown are peaks representing mTOR, raptor, and DEPTOR. (B) HEK293 cells 
were serum starved overnight and then treated for 30 min with 100 nM rapamycin. Cell 
lysates and mTOR IP were analyzed by western blotting. 
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Figure II.6. PA displaces DEPTOR from mTORC1 to activate signaling. (A) HEK293 
cells were transiently transfected with Flag-DEPTOR, serum starved overnight, and 
stimulated with 300 µM C8PA vesicles for 30 min. Cell lysates were analyzed by western 
blotting, and the ratio of pT389-S6K1 versus total S6K1 was calculated based on band 
intensities. (B) HEK293 cells stably expressing Flag-DEPTOR were starved overnight and 
then stimulated with 300 µM C8PA for 30 min. Cell lysates and raptor immunoprecipitates 
were analyzed by western blotting. (C) HeLa cells were infected with lentivirus expressing a 
negative control- or DEPTOR-shRNA and selected with puromycin for 4 days. The cells 
were then serum starved overnight and stimulated with 300 µM C8PA for 30 min. Cells 
lysates were analyzed by western blotting, and the ratio of pT389-S6K1 versus total S6K1 
was calculated based on band intensities. Data are mean ± SD. Statistical significance was 
found when comparing other samples to control (control shRNA and no C8PA), but not 
when comparing those samples with each other. (D) HEK293 cells stably expressing Flag-
DEPTOR-WT or Flag-DEPTOR-13A were serum starved overnight and stimulated with 10% 
serum for 30 min. Cell lysates and raptor immunoprecipitates were analyzed by western 
blotting. (E) HEK293 cells stably expressing Flag-mTOR-RR or FlagmTOR-RR/KI were 
serum starved overnight, and then stimulated with 10% serum in the presence of 100 nM 
rapamycin for 30 min. Cell lysates and Flag immunoprecipitates were analyzed by western 
blotting. (F) HEK293 cells were serum starved overnight and stimulated with 10% serum for 
the times indicated, followed by raptor IP and analysis by western blotting. 
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Figure II.7. Mitogens induce acute mTORC1 activation by displacing DEPTOR. (A) 
HeLa cells were infected with lentivirus expressing a negative control- or DEPTOR-shRNA 
and selected with puromycin for 4 days, followed by serum starvation overnight and 
stimulation with various mitogens for 30 min. Cell lysates were analyzed by western blotting. 
(B) HeLa cells were starved overnight and stimulated for 30 min with 300 µM C8PA. Cell 
lysates and raptor IP were analyzed by western blotting. 
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Figure II.8. Unsaturated PA species displace DEPTOR and activate mTORC1. (A) 
HEK293 cells were serum starved overnight and stimulated with 300 µM vesicles of the indicated PA 
species for 30 min. Cell lysates were analyzed by western blotting, and the ratio of pT389-S6K1 
versus total S6K1 was calculated based on band intensities measured by densitometry. (B) mTORC1 
was isolated by raptor IP from serum-starved cells and subjected to in vitro kinase assays using a 
GST-S6K1 peptide as substrate. Vesicles of various PA species were added to the kinase reactions at 
300 µM. pT389-S6K1:GST-S6K1 ratios were calculated as in (A). (C) HEK293 cells were treated as 
in (A), and raptor immunoprecipitates were analyzed by western blotting. DEPTOR:mTOR ratios 
were calculated based on band intensities measured by densitometry. Data in (A-C) are mean ± SD, 
and one-sample t-tests were performed to compare each data point to control (no PA). (D) Bacterially 
purified FRB protein was combined with SUVs of the indicated PA species for 30 min. The reaction 
mixture was then run on a Sephracryl-300 column to separate vesicle-bound (Fractions 19-22) and 
unbound (Fractions 30-36) FRB. Protein levels in collected fractions were analyzed by silver staining. 
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Figure II.9. Rapid mTORC1 activation via DEPTOR displacement. In response to 
cellular stimulation by growth factors or amino acids, unsaturated PA species are produced 
by PLD1 and selectively bind to the FRB domain of mTORC1, displacing DEPTOR and thus 
activating mTORC1 signaling. Activation of mTORC1 via DEPTOR displacement occurs 
within minutes of stimulation and lessens over time as DEPTOR re-associates.	  
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CHAPTER III. PHOSPHATIDIC ACID DEPENDENCE OF CANCER-ASSOCIATED 
HYPERACTIVATING MTOR POINT MUTATIONS 
 
III.1. Introduction 
As a master regulator of cellular processes, it is essential that mTOR is able to sense 
and respond to changes in cell status and resource levels. It is well established that mTORC1 
activity is positively correlated with the availability of growth factors and amino acids, and is 
downregulated by osmotic, oxidative, and hypoxic stress (Reiling and Sabatini, 2006). In the 
presence of growth factors, like insulin, Ras and PI3K signaling is initiated, leading to 
increased activity of AKT, ERK, and RSK1. All three kinases phosphorylate the TSC1/2 
complex, promoting the accumulation of the GTP-bound form of the small Ras-related 
GTPase, Rheb, which subsequently activates mTORC1. mTORC1 activation by growth 
factors requires the presence of amino acids, constituting a practical restriction whereby 
cellular machinery does not respond to catabolic signals in the absence of sufficient resources 
for protein synthesis. The communication of amino acid levels to mTORC1 is a multi-faceted 
process that, in recent years, has been revealed to involve at least 2 parallel pathways that 
converge at the lysosomal surface. The two signaling pathways are characterized by 1) class 
III PI3K Vps34 and PLD1 (Yoon et al., 2011a) and 2) Ragulator and Rag proteins 
(Chantranupong et al., 2016). 
PLD1 is localized to the lysosome in the presence of amino acids and is a critical 
effector of the amino acid-sensing Vps34 pathway, as well as Rheb signaling to mTORC1. 
Once activated by growth factors or amino acids, PLD1 catalyzes the hydrolysis of PC to the 
lipid second messenger PA (Jenkins and Frohman, 2005), which binds to the FRB domain of 
mTOR and activates mTOR kinase activity by a partially understood mechanism involving 
the displacement of the endogenous inhibitors FKBP38 and DEPTOR (Fang et al., 2001; 
Yoon et al., 2011b, 2015). 
Aberrant PA signaling is linked to cancer, diabetes, and Alzheimer’s disease (Jin et 
al., 2006, 2007; Zhang and Frohman, 2014; Zhang et al., 2012) and mutations in positive and 
negative components of the amino acid sensing pathways upstream of mTOR have been 
linked to the pathogenesis of several diseases (Bar-Peled and Sabatini, 2012). Mutations in 
mTOR itself, however, were not thought to be functionally correlated with the development 
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of disease until recently when several hyperactivating mTOR mutations were shown to 
confer tumorigenicity or were identified in human cancers (Grabiner et al., 2014; Murugan et 
al., 2013; Sato et al., 2010). To date, over 20 point mutations spanning the C-terminal half of 
mTOR have been confirmed to hyperactivate mTOR signaling in cells, and many of these 
point mutations have been identified within human cancer genome databases (Grabiner et al., 
2014; Murugan et al., 2013; Ohne et al., 2008; Sato et al., 2010). Many of the mutations, 
which occur within the FAT, FRB, PIKK, and FATC domains alike, exist within small 
clusters. Despite exhibiting variation with regards to their extent of hyperactivation and their 
interaction with the endogenous inhibitor DEPTOR, all hyperactive mTOR mutants studied 
are reported to remain sensitive to inhibition by rapamycin. Thus, there appear to be different 
mechanisms of hyperactivation conferred by point mutations at different mTOR residues, 
none of which are sufficient to promote substrate phosphorylation in the presence of 
rapamycin. 
While previous studies have provided important identification, characterization, and 
correlation data for hyperactivating mTOR mutations, remarkably little is known about the 
molecular mechanisms by which these mutations hyperactivate mTOR. Mutations at the 
S2215 residue were found to be the most commonly occurring mTOR mutations in the 
COSMIC database (Grabiner et al., 2014), with the S2215Y mutation reported to be one of 
the most hyperactivating point mutations (Grabiner et al., 2014; Sato et al., 2010). 
Interestingly, Sato et al. found that the S2215Y mutation confers resistance to 1-butanol 
treatment, implying that S2215Y mTOR activity may be independent of PLD1 and PA. 
Indeed, S2215Y, E2419K, and R2505P (L1460P was not investigated) are all reported to 
specifically hyperactive mTORC1 signaling, without affecting mTORC2 signaling (Sato et 
al., 2010), which we know does not involve PA (Fang et al., 2001; Yoon et al., 2011b). The 
mechanism by which S2215Y hyperactivates mTORC1 requires further probing, and the 
possibility that point mutations other than S2215Y confer PA-independence has not, to our 
knowledge, been investigated. Our motivation for conducting such a study is twofold. First, 
this information, together with our structural knowledge of mTOR and the mTORC1 
homodimer, could provide mechanistic insight regarding the regions or conformational 
changes within mTOR that accompany its activation by PA. Second, we believe that the 
PLD-dependence of hyperactive mTOR mutants has important implications for therapeutic 
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strategies and that the characterization of such dependence can inform treatment strategies 
for mutant mTOR-associated cancers.  
In this chapter, I describe our investigation into the nature of four hyperactivating 
mutants: L1460P, E2419K, S2215Y, and R2505P, with particular emphasis on dissecting 
their individual dependence on PLD1 and PA. My studies indicate that these mutations, 
which are located in different domains of the protein, differ in their response to PLD1 
inhibition. While three of the hyperactive mutants remain relatively sensitive to PLD1 
inhibition, the S2215Y mutant displays significant PA-independent mTORC1 activity, 
implicating the region surrounding the S2215 residue in the mechanism of mTOR activation 
by PA and supporting the notion that hyperactivating mTOR mutations should be taken into 
account when considering PLD inhibition as a cancer therapy. I also identified a striking 
increase in the autophosphorylation of the R2505P mutant, a hyperactivation specific to only 
one of the four mutants examined. The varied activity levels and substrate preferences of the 
mTOR mutants in response to amino acid starvation or PLD inhibition suggest that there are 
multiple mechanisms by which mTOR activity can be regulated.  
 
III.2. Materials and Methods 
 
III.2.1. Antibodies and Other Reagents 
All antibodies used in this study were obtained from the following commercial 
sources: anti-AU1 from Bethyl Laboratories, Inc., anti-raptor from EMD Millipore, anti-GST 
from Santa Cruz Biotechnology, and anti-tubulin from Abcam. All secondary antibodies 
from Jackson ImmunoResearch. All other antibodies from Cell Signaling. Protein G-agarose 
was from Millipore. PA was purchased from Avanti Lipids. All other reagents were 
purchased from Sigma-Aldrich. 
 
III.2.2. Plasmids 
AU1-tagged rat mTOR cDNA constructs were obtained from Addgene: plasmid 
26036 (pcDNA3-AU1-mTOR-WT), plasmid 19995 (pcDNA3-AU1-mTOR-L1460P), 
plasmid 26037 (pcDNA3-AU1-mTOR-S2215Y), plasmid 19994 (pcDNA3-AU1-mTOR-
E2419K), and plasmid 26038 (pcDNA3-AU1-mTOR-R2505P) (Sato et al., 2010; Urano et 
	 52	
al., 2007). pRK5-HA-raptor was also obtained from Addgene: plasmid 8513 (Kim et al., 
2002). pcDNA3 was used as the empty vector control. GST-S6K1 (amino acids 332-421) 
HA-S6K1, and Flag-4EBP1 were already described in (Yoon et al., 2011b), (Brown et al., 
1995), and (Kim and Chen, 2000) respectively.  
 
III.2.3. Cell Culture 
HEK293 cells were maintained in DMEM containing 10% fetal bovine serum (FBS) 
at 37 °C with 5.5% CO2. Transfections were performed with Polyfect (Qiagen) following the 
manufacturers’ recommendations. Serum starvation was achieved by incubating cells in 
serum-free DMEM overnight, and 10% FBS was used for serum stimulation. Amino acid 
starvation was achieved by incubating cells in amino acid-free DMEM containing dialyzed 
FBS for two hours, and normal growth media was used for amino acid stimulation.  
 
III.2.4. Immunoprecipitation (IP) 
For IP, cells were lysed in ice-cold lysis buffer (40 mM HEPES, pH7.4, 120 mM 
NaCl, 10 mM sodium pyrophosphate, 50 mM NaF, 10 mM beta-glycerophosphate, 2 mM 
EDTA, 1x protease inhibitor cocktail (PIC) (Sigma-Aldrich), and 0.3% CHAPS). Upon cell 
lysis, the lysate supernatant was collected after centrifugation at 10,000g for 10 minutes and 
subjected to IP at 4 °C with an AU1 antibody for 2 hours, followed by IP with protein G 
Sepharose for 1 hour. Sepharose-bound proteins were washed 3 times in lysis buffer and then 
were either mixed with SDS sample buffer containing 5% final concentration of 2-
mercaptoethanol, or were washed 2x in kinase assay buffer and subjected to an mTORC1 
kinase assay as described in III.2.7. 
 
III.2.5. Cell lysis and Western Blotting 
To make lysates for western blotting only, cells were lysed in 20 mM Tris-HCl at 
pH7.5, 0.1 mM Na3VO4, 25 mM NaF, 25 mM glycerophosphate, 2mM EGTA, 0.3% Triton 
X-100. Upon cell lysis, the lysate supernatant was collected after centrifugation at 10,000g 
for 10 minutes, and mixed with SDS sample buffer containing 5% final concentration of 2-
mercaptoethanol. All samples were boiled for 5 minutes, except samples to be probed with a 
PLD1 antibody; proteins were resolved on SDS-PAGE and transferred onto PVDF 
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membranes (Millipore). Antibody incubations were performed at 4 degrees Celsius overnight 
in 5% skim milk in PBS with 0.05% Tween. Detection of horseradish peroxidase-conjugated 
secondary antibodies was performed with chemiluminescence solution (100 mM Tris-HCl, 
0.009% H2O2, 225 µM coumaric acid, 1.25 mM luminol). Images were developed on x-ray 
films. Quantification of band intensities was performed by densitometry of film images using 
the Image J software. 
 
III.2.6. Lipid Vesicle Preparation 
16:0-18:1 PA was purchased from Avanti Polar Lipids, Inc. in chloroform. PA 
vesicles were prepared as previously described (Yoon et al., 2011b) by water bath sonication, 
at a final concentration of 1 mM. 
 
III.2.7. In Vitro mTORC1 Kinase Assay 
mTORC1 was immunoprecipitated with an AU1 antibody and the kinase assays were 
performed as previously described (Yoon et al., 2011b), with 100 ng GST-S6K1 as the 
substrate. Where applicable, PA vesicles or vesicle buffer were added to the washed 
immunocomplexes 15 minutes before initiation of the kinase assay by the addition of ATP. 
 
III.2.8. Lentivirus-mediated RNAi 
Lentiviral shRNA plasmids used in this study were in the pLKO.1puro vector and 
obtained from Sigma-Aldrich (Mission® shRNA). The human PLD1 shRNA 
(TRCN0000001011) and the negative control shRNA (scrambled hairpin sequence) were 
previously described (Yoon et al., 2011a). Viral packaging, infection, and puromycin 
selection of infected cells were performed as previously described (Yoon et al., 2011a). 
 
III.2.9. Statistical Analysis 
All quantitative data are presented as mean ± standard deviation (SD) of at least three 
independent experiments. Statistical significance of the data was analyzed by performing a 
one-or two-tailed Student’s t test as indicated. 
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III.3. Results 
 
III.3.1. Point Mutations Within mTOR’s FAT, PIKK, and FATC Domains Confer 
Hyperactivity 
Since the growth factor and nutrient resistance of L1460P, E2419K, S2215Y, and 
R2505P mTOR mutants were not previously tested side by side, I cotransfected HEK293 
cells with HA-S6K1 and each of the four mTOR mutants and examined the relative levels of 
S6K1 phosphorylation in the lysates of growth factor- or amino acid-starved cells by 
immunoblotting. As expected, all four mutants exhibited some degree of hyper mTORC1 
activity in either starvation condition (Figure III.1A&B). To rule out any complications that 
could be introduced by S6K1’s ability to autophosporylate, I also examined all four mutant 
mTORs’ hyperactivity toward cotransfected Flag-4EBP1 in amino acid starved cells. Indeed, 
each of the mutants promoted amino acid-independent phosphorylation of Flag-4EBP1, as 
evidenced by an electrophoretic retardation of the total Flag-4EBP1 protein (Figure III.1C). 
These experiments confirm the growth factor- and amino acid-independent mTORC1 activity 
previously reported for L1460P, E2419K, S2215Y, and R2505P mTOR mutants, and reveal 
that the S2215Y mutation confers the greatest hyperactivity, followed by R2505P, L1460P, 
and E2419K.  
It is unclear from the current published work whether these mTOR mutations 
generate constitutively active mTOR, or simply confer a limited degree of hyperactivity. 
While the L1460P, E2419K, S2215Y, and R2505P mTOR mutants have been deemed 
constitutively active (Grabiner et al., 2014; Sato et al., 2010; Urano et al., 2007), their 
activity was not tested beyond 1 hour of amino acid withdrawal and may well decrease by 
later time points. In another study, E2419K mTOR hyperactivity toward S6K1 was reported 
to return to basal levels after only 20 minutes of amino acid starvation and hyperactive 
mTORC1 signaling conferred by other point mutations (which I did not address in my 
investigation) decreased over the course of 3 hours (Ohne et al., 2008). Additionally, Sato et 
al. reported that S2215Y mTOR, while resistant to nutrient withdrawal, remains sensitive to 
oxidative and osmotic stress, indicating that the mutant mTOR is not completely unregulated 
(Sato et al., 2010). Thus, there is evidence that at least some cancer-associated point 
mutations in mTOR confer hyperactivity, rather than constitutive activity.  
	 55	
To probe this dimension of the mTORC1 activity conferred by the L1460P, E2419K, 
S2215Y, and R2505P mutations, I examined the phosphorylation of Flag-4EBP1 in cells 
expressing the four mutant mTORs over the course of several hours of amino acid starvation. 
Based on the band-shift of the Flag-4EBP1 protein, all four of the mTOR mutants remained 
catalytically active toward 4EBP1 after three hours, the longest duration of hyperactivity that 
has been reported for any mutants to date. Flag-4EBP1 phosphorylation persisted after six 
hours of amino acid starvation. Twelve hours after amino acids were withdrawn, Flag-4EBP1 
phosphorylation in all mutant mTOR-expressing cells was decreased, resulting in a 
condensation of the Flag-4EBP1 protein signal to tighter bands that more closely resembled 
the controls (Figure III.1D). It should be noted that the data presented in Figure III.1D only 
represent a single experiment and therefore merely suggest but by no means prove that each 
of the point mutations examined confer hyper mTORC1 activity, rather than constitutive 
kinase activity. 
 
III.3.2. S2215Y is a Unique Hyperactivating Point Mutation That Confers PLD1-
Independence 
 Previously, we have shown that PLD1 and PA are critical mediators of mTORC1 
activation by growth factors as well as amino acids (Fang et al., 2001, 2003; Sun et al., 2008; 
Yoon et al., 2011a), and that PLD1-produced PA binding directly stimulates mTORC1 
kinase activity (Yoon et al., 2011b, 2015). We hypothesized, therefore, that any or all of the 
hyperactive mTOR mutants may be resistant to starvation by way of a reduced dependence 
on PA production by PLD1. We envision two possible mechanisms that could achieve this: 
1) a point mutation could increase mTOR’s affinity for PA and thereby allow the kinase to 
remain active even once PA production has ceased, or 2) a point mutation could cause the 
mTOR protein to adopt a conformation that mimics the PA-bound conformation of WT 
mTOR, such that the mutant protein no longer requires PA. The finding by Sato et al. that 
S2215Y mTOR remains active even when the transphosphatidylation reaction that generates 
PA is inhibited by the addition of 1-butanol (Sato et al., 2010) suggests that at least one 
hyperactivating mTOR mutation may be independent of regulation by PA and warrants 
similar investigation of other mutations.  
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 I began by examining the effect of 1-butanol treatment on the growth factor-
stimulated mTORC1 activity of L1460P, E2419K, S2215Y, and R2505P mTOR transfected 
cells. Previously, I and others in our group have shown that 0.3% 1-butanol is sufficient to 
significantly inhibit mTORC1 activity in HEK293 cells (Fang et al., 2001; Yoon et al., 
2015). As shown in Figure III.2.A, the E2419K and S2215Y mutants exhibited striking 
mTORC1 activity in the presence of 0.3% 1-butanol, while the activity of the other two 
mutants is very low, similar to the empty vector and WT mTOR controls. It is interesting to 
note that while the R2505P mutation conferred hyperactivity similar to that of the S2215Y 
mutant in cells starved of growth factors (Figure III.1A), the two mutants showed drastically 
different responses to PLD inhibition with 1-butanol (Figure III.2A). The divergent responses 
of these mTOR mutants are indicative of different dependencies on PA, but this experiment 
needs to be repeated before a firm conclusion can be drawn. 
To investigate the PA dependence of the mTOR mutants within the context of amino 
acid signaling, I transfected HEK293 cells with each mTOR mutant and starved or stimulated 
of amino acids with or without 1-butanol present. In contrast to the cells with co-transfected 
S6K1 described in Figure III.1B, no hyperactive phosphorylation of endogenous S6K1 was 
detected in amino acid starved cells (Figure III.2B). This difference could be the result of a 
longer 1-butanol treatment, or could be an indication that the degree of amino acid-
independent mTORC1 activity conferred by the expression of mTOR mutants in a small 
fraction of the total cellular context of the sample is not great enough to be detected. When 
the cells where stimulated with amino acids in the presence of 1-butanol, a significant level 
of phosphorylated endogenous S6K1 was detected in the S2215Y mTOR expressing cells. 
Comparing the amino acid-starved, -stimulated, and the 1-butanol treated samples, it appears 
that, when receiving all amino acid sufficiency signals other than PA, the S2215Y mTOR 
mutant exhibits catalytic activity similar to that of amino acid stimulated WT mTOR. This 
data indicates that the S2215Y mutation renders mTORC1 independent of PA and is 
consistent with the report from Sato et al. that S2215Y mTOR is resistant to 0.8% 1-butanol 
in growth factor starved cells (Sato et al., 2010). At times, I have also observed very mild 
phosphorylation of endogenous S6K1 in 1-butanol-treated cells expressing L1460P, E2419K, 
or R2505P. However, this resistance is not as strong, nor nearly as consistent as the 
resistance conferred by S2215Y mTOR.  
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 I also investigated the activity of each mutant toward cotransfected Flag-4EBP1 in 
cells stimulated with amino acids and treated with 1-butanol. Under these conditions, all four 
mutants conferred mild resistance to 1-butanol treatment, as evidenced by the distribution of 
Flag-4EBP1 in both fast- and slow-migrating bands (Figure III.2C). Consistent with my 
observations of endogenous S6K1 phosphorylation, S2215Y mTOR was the most 
hyperactive mutant toward Flag-4EBP1 in the presence of 1-butanol. 
Though used to probe PLD function for many years, 1-butanol has been demonstrated 
to be both an incomplete and non-specific PLD inhibitor with several off-target effects 
(Zhang and Frohman, 2014). We therefore chose to further scrutinize the PLD-dependence of 
the mTOR mutants by employing the PLD-specific inhibitor, FIPI. As reported previously 
(Yoon et al., 2015), and demonstrated in Figure III.3A, 30uM FIPI completely inhibited the 
amino acid stimulated activity of endogenous and overexpressed WT mTOR. Despite such 
complete WT inhibition, S2215Y mTOR expressing cells consistently contained a significant 
amount of phosphorylated endogenous S6K1 and Flag-4EBP1 after FIPI treatment (Figure 
III.3A&B), corroborating the analogous 1-butanol data. Consistent with FIPI being a more 
complete inhibitor of PLD1 than 1-butanol, L1460P, E2419K, and R2505P mTORC1 
activities toward endogenous S6K1 or Flag-4EBP1 were more sensitive to FIPI treatment 
than 1-butanol treatment. Cells expressing these three mutants occasionally exhibited some 
mTORC1 signaling in the presence of FIPI, especially E2419K. Intriguingly, I often 
observed that FIPI treatment actually increased the mTORC1 signaling in cells expressing 
the S2215Y mTOR mutant (note the intensity increase of the slowest migrating Flag-4EBP1 
band in the S2215Y/FIPI lane of Figure III.3A and see Figure III.3C). The fact that I only 
observed this increase in activity when cotransfecting mTOR with a substrate indicates that it 
is a relatively subtle effect. Please see the Discussion for interpretation of this surprising 
effect. 
 PLD1 and PLD2 are two isoforms of the PLD enzyme with distinct subcellular 
localization and roles. To specifically investigate the regulation of the mTOR mutants with 
regards to the PLD1 isoform as well as to seek evidence independent of pharmacological 
inhibition, I conducted shRNA-mediated knockdown of the PLD1 protein and examined the 
phosphorylation of HA-S6K1 in cells also expressing the different mTOR proteins. My 
preliminary data reveal that cells expressing L1460P, S2215Y, or E2419K mTOR maintain a 
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mild level of mTORC1 signaling despite PLD1 knockdown in asynchronous cells, while the 
mTORC1 activity of the R2505P mutant is highly reliant on PLD1 (Figure III.4A&B). To 
investigate if PLD1 independence underlies the amino acid-independent hyperactivity of any 
of the mTOR mutants, I also performed this experiment in the context of amino acid 
starvation and re-addition. Not surprisingly, cells expressing S2215Y mTOR retained 
substantial phosphorylation of S6K1, despite PLD1 protein levels being reduced to a level 
that drastically inhibited endogenous, WT, and R2505P mTORC1 activity (Figure 
III.4C&D). Cells expressing E2419K mTOR exhibited PLD1-independent mTORC1 
signaling similar that of S2215Y mTOR, though the E2419K cells contained slightly more 
S6K1 substrate. Taken together with the 1-butanol and FIPI data, it appears that the L1460P 
and E2419K mutations lend mTOR mild PA-independence that may be limited by the 
concentration of cellular PA or the imposition of other inhibitory factors. These data also 
indicate that substituting a tyrosine for the normally occurring serine at mTOR’s 2215 
residue renders mTOR capable of PA-independent mTORC1 kinase activity and, therefore, 
free of PLD1 regulation, while replacing the arginine at 2505 with a proline hyperactivates 
mTOR by an entirely different mechanism.  
 We reasoned, therefore, that the catalytic activity of S2215Y mTOR should be 
unaffected by the absence or addition of PA in vitro. To test this hypothesis, I overexpressed 
WT or S2215Y mTOR together with HA-raptor in HEK293 cells and isolated the mTORC1 
complexes by immunoprecipitating the AU1 mTOR. I then subjected the respective isolated 
mTORC1 complexes to in vitro kinase assays in the presence or absence of small unilamellar 
PA vesicles. As shown in Figures III.5A and B, WT mTOR activity toward GST-S6K1 was 
very low in the absence of PA and was significantly increased if PA was included in the 
reaction. Conversely, S2215Y mTOR catalyzed distinct phosphorylation of the GST-S6K1 
peptide regardless of PA. These in vitro data corroborate our conclusions from the PLD 
inhibition experiments that the S2215Y mutation promotes mTORC1 activity even in the 
absence of PA. 
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III.3.3. R2505P is a Unique Mutation That Confers Distinct Hyperactivity for mTOR 
Autophosphorylation 
 S6K1 and 4EBP1 are best-characterized substrates of mTORC1. Both substrates are 
recruited and presented to mTORC1 by the mTORC1 component, raptor, as characteristic 
common to other, less studied, mTORC1 substrates. mTOR also catalyzes the 
autophosphorylation of S2481 located within an unstructured segment of its kinase domain 
(Peterson et al., 2000) and there is substantial evidence that this occurs within mTORC2 as 
well as mTORC1, indicating that raptor is not required for this autophosphorylation (Copp et 
al., 2009; Soliman et al., 2010). Given this evidence that the substrate phosphorylation and 
autophosphorylation catalyzed by mTORC1 differ in their regulation, we wanted to 
investigate the autophosphorylation activity of each of the mTOR mutants. As shown in 
Figures III.6, R2505P was the only point mutation that resulted in autocatalytic activity 
toward S2481 that was substantially greater than that of WT mTOR in amino acid stimulated 
cells. While S2481 phosphorylation was hardly detected in amino acid starved cells 
expressing WT mTOR or any of the other mutant mTORs, it clearly persisted in starved cells 
expressing the R2505P mutant. In fact, the R2505P mTOR autophosphorylation in these cells 
remained even greater than that of amino acid stimulated WT mTOR. Intriguingly, R2505P 
mTOR’s autocatalytic activity also remained relatively unaffected by FIPI or 1-butanol 
treatment, both of which significantly reduce R2505P mTOR’s phosphorylation of S6K1 or 
recombinant 4EBP1 (See Figures III.2 & III.3). Thus, it appears that the R2505P mutation 
confers mTOR hyperactivity by a mechanism that promotes PA-independent 
autophosphorylation but still requires PA for the phosphorylation of mTORC1 substrates.  
 
III.4. Discussion 
 
III.4.1. mTORC1 Hyperactivity Conferred by Point Mutations Remains Sensitive to 
Some Regulation 
 Herein we have shown for the first time the hyper- mTORC1 activity conferred by the 
point mutations L1460P, S2215Y, E2419K, and R2505P decreases after prolonged (12 hour) 
nutrient starvation. In light of this finding, we consider these point mutations to be 
hyperactivating, rather than constitutively activating within the cellular context. It should be 
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noted that Ohne et al. previously reported a much more rapid loss of E2419K mTORC1 
hyperactivity initiated by 20 minutes after amino acid withdrawal (Ohne et al., 2008). The 
differences between my observations and those made by Ohne et al. may simply stem from 
the different signaling contexts of the cells used (HEK293 cells with growth factors present 
vs. HeLa cells with growth factors removed) or, perhaps, the different substrates examined 
(Flag-4EBP1 vs. HA-S6K1). 
 The hyper-mTORC1 activities conferred by these mTOR mutations could decrease 
over time either because: 1) a positive regulator (like PA) that a mutant binds with an 
abnormally high affinity is eventually eliminated (e.g., by a phosphatase), or 2) a mutation-
induced conformational change that mimics the active form of mTOR within mTORC1 is 
ultimately subjected to other inhibition within the cellular context. Our preliminary 
investigation into the hyperactivation cannot differentiate between those two possibilities. To 
ask whether a mutant binds simply binds PA more tightly, we could manipulate PA levels 
with chemical PLD inhibitors before beginning the starvation, or we could expedite PA 
elimination by overexpressing a PA phosphatase. 
 
III.4.2. Structural and Mechanistic Insights 
Our investigation of the PLD-dependence of various mTOR proteins containing point 
mutations (see Figure III.7 for locations) has revealed a range of requirements for PLD 
activity. The two mutants that displayed the lowest level of hyperactivity, L1460P and 
E2419K, both appear to have some PLD independence. One apparent inconsistency in my 
data is that while I detected PLD-independent E2419K mTORC1 activity toward Flag-
4EBP1, I found that the same mutant relied on PLD activity for the phosphorylation of 
endogenous S6K1 (compare Figure III.2 B&C, and see Figure III.3). It may be that the PLD-
independent hyperactivity of E2419K is so mild that it cannot be detected without 
cotransfecting an mTORC1 substrate (as I did with Flag-4EBP1), or these data may point to a 
difference in the mechanisms of S6K1 and 4EBP1 phosphorylation. These hypotheses could 
be further tested by repeating the experiment shown in Figure III.2 B&C and Figure III.3 
using HA-S6K1 instead of Flag-4EBP1.  
It is interesting that E2419K mTOR was resistant to 40 minutes of 1-butanol 
treatment in growth factors starved cells with intact amino acid signaling but was 
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significantly inhibited by 2.5 hours of 1-butanol treatment in amino acid starved cells (see 
Figure III.2A&B). This difference could stem from the nature of the starvation used, or the 
length of PLD inhibition used. Differences resulting from the kind of starvation used would 
imply that E2419K mTOR hyperactivity is more sensitive to the removal of amino acids than 
the removal of growth factors. On the other hand, if it is really the duration of PLD inhibition 
that matters, this could indicate that having some PA around initially is important for hyper- 
E2419K mTORC1 activity, and suggest that the hyperactivity might be the result of tighter 
PA-binding. 
How substituting a lysine for the normally occurring glutamate at position 2419 
would increase mTOR’s affinity for PA is unclear, since residue 2419 falls within the kα9a 
helix that runs along the base of the kinase C-lobe before turning into the kα9b helix that 
reaches up toward the catalytic cleft (Figure III.8). The E2419K mutation could certainly 
cause a structural change in the protein. Glutamate is a negatively charged amino acid while 
lysine is positively charged with a longer side chain. Both amino acids are commonly 
involved in stabilizing protein structure via hydrogen bonding when located within the core 
of a protein, but the two form salt bridges with entirely different amino acids. Yang et al. 
have confirmed that the E2419K mutation eliminates the E2419/R1905 salt bridge between 
kα9a and the FAT domain (Yang et al., 2013). 
The other mutation with mild hyperactivation and PLD-independence, L1460P, was 
reported by Grabiner et al. to reduce DEPTOR binding to mTOR (Grabiner et al., 2014). This 
could explain why L1460P retains some activity in amino acid stimulated cells with inhibited 
PA production (Figures III.2C, III.3, and III.4), because part of PA’s role in activating 
mTORC1 is displacing DEPTOR (Yoon et al., 2015). It is interesting that the R2505P 
mutation, which, compared to L1460P, is located at the opposite end of mTOR’s C-terminus, 
was also reported to bind less DEPTOR (Grabiner et al., 2014). Other than this reduced 
interaction with DEPTOR, the two mutations seem to have little in common. I observed that 
R2505P confers stronger hyperactivity than L1460P in starvation conditions, yet is more 
sensitive to PLD1 inhibition. Additionally, the R2505P mutation confers strong hyper-
autocatalytic activity that does not accompany the L1460P mutation. Thus, while both 
L1460P and R2505P mutations may activate mTORC1 in part by preventing DEPTOR 
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binding, the R2505P mutations appears to confer additional hyperactivity by a separate 
mechanism.  
Arginine 2505 is a positively charged amino acid whose side chain most likely points 
away from the core of the protein and forms salt-bridges with surrounding aspartate or 
glutamate residues to stabilize mTOR’s kα10 helix. Mutating this residue to proline, which is 
an imino acid that cannot adopt a normal helical conformation, would certainly affect the 
structure of the kα10 helix – most likely by introducing an abrupt turn or kink. Given the 
location of kα10 within the mTOR protein, this kind of conformational change could 
interfere with DEPTOR binding and simultaneously affect mTOR’s kinase activity. The 
kα10 helix lies near the base of mTOR’s catalytic cleft and is directly connected via an 
unstructured segment containing S2481 to the kα9b helix, which is believed to negatively 
regulate mTOR by plugging one side of the catalytic cleft (Yang et al., 2013). Our findings 
suggest that whatever conformational change accompanies the R2505P mutation likely 
improves S2481 access to mTOR’s catalytic site and orients kα9b in such as way as to 
promote substrate access, presuming PA is bound to the FRB domain. 
Finally, regarding the S2215Y mutation, we conclude that this mutation 
hyperactivates mTORC1 by a mechanism that eliminates the requirement of the kinase for 
PA. Similar to E2419, this residue is located near the base of the kinase C-lobe, albeit within 
the center of the mTORC1 complex. Therefore, how this mutation could influence the PA 
binding or the orientation of the FRB domain is not immediately obvious. However, S2215 is 
located within a tight turn that then loops back along the bottom of the catalytic cleft as an 
unstructured segment that connects to a few β-sheets near the base of the FRB domain 
(Figure III.9 and III.10). Small amino acid that it is, serine is often found in tight turns like 
this and can actually hydrogen bond to the protein backbone. Mutating S2215 to a more 
hydrophobic residue of twice the size, like tyrosine, would inevitably interfere with the 
structure and angle of the turn, transmitting tension and strain through the unstructured 
segment to the β-sheets at the base of the FRB domain and the mouth of the catalytic cleft. 
The FRB domain forms one of the two walls of mTOR’s deep catalytic cleft, restricting 
random substrate access to the kinase’s active site (Aylett et al., 2016; Yang et al., 2013). In 
light of the FRB domain’s steric restriction of the catalytic cleft, we believe mTORC1 
activation by PA-FRB binding might involve a conformational change that opens up cleft 
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access. It is possible that the S2215Y mutation substitutes for PA binding by altering the 
conformation of the mTOR kinase domain and subsequently the orientation of the FRB 
domain, opening up substrate access to the catalytic cleft in a similar manner as PA-FRB 
binding. Alternatively, the S2215Y mutation may affect the orientation of the C-lobe αhelix 
comprised of residues 2247-2257. This is an intriguing possibility, since this αhelix extends 
out toward raptor from the base of the C-lobe, near the mouth of the catalytic cleft, and may 
ordinarily restrict cleft access (Figure III.10). In either of these models, PA binding could 
still promote additional catalytic activity, either by opening up cleft access even further or by 
displacing FKBP38 or DEPTOR, which was reported to bind S2215Y mTOR (Grabiner et 
al., 2014). 
The fact that I repeatedly observed FIPI treatment actually increasing S2215Y 
mTORC1 signaling (Figure III.3C), is consistent with this mutant being further activated by 
the removal of endogenous inhibitors. Upon PLD inhibition with 30uM FIPI, cellular PA 
levels would be extremely low and the majority of WT mTOR would be bound to FKBP38 
and DEPTOR, possibly sequestering these endogenous inhibitors. In such a setting, 
overexpressed S2215Y mTOR, which remains active in the absence of PA, might be further 
activated by reduced interaction with free DEPTOR molecules.  
 
III.4.3. Implications of Unique Hyperactivating mTOR Mutations in Cancer 
There have been several suggestions for the use of PLD inhibitors as cancer 
therapeutics – both generally (Zhang and Frohman, 2014), and specifically in hepatocellular 
carcinoma (HCC) (Xiao et al., 2016), breast cancer (Cheol Son et al., 2013; Henkels et al., 
2013; Toschi et al., 2010), and kidney cancer (Toschi et al., 2010). While PLD inhibition will 
likely confer a range of therapeutic benefits, including benefits not mediated by mTOR 
(Zhang and Frohman, 2014), the possible presence of PLD-independent mTOR should be 
taken into account when devising a treatment strategy. The MTOR gene was found to contain 
the highest frequency of recurring mutations of any gene in the mTOR signaling pathway 
(Grabiner et al., 2014), and the same study identified the S2215 residue as the site of the most 
recurring point mutations within mTOR. Together with our finding that the S2215Y mTOR 
mutation confers hyperactivity even in the absence of PA, the possibility of PLD-
independent mTOR activity in human cancer cells warrants consideration. In cases where an 
	 64	
S2215Y mutation is present, PLD or PLD1 inhibition would likely selectively promote the 
mTORC1 signaling and, thus, the growth, proliferation, and survival of the mutant-
containing cancer cells.  
Another recent suggestion pertaining to the clinical importance of mTOR signaling in 
cancer is the use of mTOR autophosphorylation at S2481 as a biomarker for screening tissues 
for aberrant mTOR signaling (Soliman et al., 2010). Our discovery that mTOR containing a 
proline in place of an arginine at residue 2505 exhibits disproportionately higher kinase 
activity toward S2481 than toward functional downstream substrates indicates that point 
mutations, especially those within the region of amino acids comprising the k9 and k10 
helices may exhibit distinctly different catalytic activities toward substrates and 
autophosphorylation sites. In fact, my data indicate that while R2505P mTOR is unique in 
exhibiting much higher activity for autophosphorylation than toward substrates, the other 
mTOR mutants examined also exhibit disproportionate activity toward auto- and substrate 
phosphorylation autophosphorylation but in the opposite direction. These findings lead us to 
propose that the presence of point mutations in mTOR should be considered when using 
S2481 autophosphorylation as a readout of functional mTOR signaling. In some cases, renal 
cell carcinomas in particular, it might be more informative and beneficial to screen for 
phosphorylated 4EBP1 as demonstrated and advised by Qu et al. (Qu et al., 2016), especially 
since phospho-4EBP1 has been shown to drive clear cell renal cell carcinoma (Campbell et 
al., 2015).  
These implications of mTOR mutant behavior may be especially important for the 
treatment of renal cancers which have a reportedly higher percentage of mutations in mTOR 
pathway components compared to other cancers (Creighton et al., 2013; Sato et al., 2013). 
Especially as our understanding of hyperactivating mTOR mutations expands, understanding 
the mTOR mutational landscape of a particular cancer could provide important insight into 
the requirements and susceptibilities of those cancer cells. Admittedly, the heterogeneity of 
human cancers presents an obstacle for this degree of effective genetic disease profiling. The 
heterogeneity of an mTOR hyperactivating point mutation within a human tumor has already 
been described (Gerlinger et al., 2012). Therefore, advances in our understanding of the 
development of tumor heterogeneity as well as in our ability to conduct and sequence more 
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thorough biopsies will greatly benefit attempts to discern and target the mTOR mutational 
landscape of cancers. 
 
III.5. Contributions of Co-Worker 
 Though not included herein, Lucy Yao performed several experiments, under my 
supervision, investigating hyperactive mTORC1 signaling toward endogenous S6K1 and 
4EBP1 that have informed my understanding of these four mTOR mutations. 
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III.6. Figures 
 
 
Figure III.1. Select point mutations confer varying degrees of starvation resistant 
hyperactivity to mTORC1. HEK 293 cells were transfected with empty vector (EV), wild 
type mTOR (WT), L1460P mTOR (14), S2215Y mTOR (22), E2419K mTOR (24) or 
R2505P mTOR (25) and subjected to various starvation conditions before cell lysis and 
detection of mTORC1 signaling via immunoblotting. A) 24 hours after being cotransfected 
with an empty vector or mTOR construct and HA-S6K1, cells were starved in DMEM 
lacking growth factors for 18 hours. B) Cells transfected as in A were starved for 2 hours in 
amino acid-free DMEM with 10% dialyzed serum. C) Cells cotransfected with an empty 
vector of mTOR construct and Flag-4EBP1 for 24 hours were treated as in B. D) Cells 
cotransfected with an empty vector or mTOR construct and Flag-4EBP1 were starved, as in 
B, but for the indicated times. 
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Figure III.2. Hyperactive mTOR mutants exhibit a range of sensitivities to 1-butanol. 
HEK 293 cells were transfected with empty vector (EV), wild type mTOR (WT), L1460P 
mTOR (14), S2215Y mTOR (22), E2419K mTOR (24) or R2505P mTOR (25) and subjected 
to various treatments before cell lysis and detection of mTORC1 signaling via 
immunoblotting. A) 24 hours after being cotransfected with an empty vector or mTOR 
construct and HA-S6K1, cells were starved in serum-free DMEM. 18 hours later, the cells 
were pretreated with 0.3% 1-butanol for 10 minutes, then switched to growth media 
containing 0.3% 1-butanol for 30 minutes. B&C) 24 hours after cotransfection with an empty 
vector or mTOR construct and Flag-4EBP1, cells were starved for 2 hours in amino acid-free 
DMEM with 10% dialyzed serum containing 0.3% 1-butanol. Cells were then switched to 
growth media containing 0.3% 1-butanol for an additional 30 minutes. 
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Figure III.3. S2215Y promotes FIPI resistant mTORC1 signaling. HEK 293 cells were 
transfected with empty vector (EV), wild type mTOR (WT), L1460P mTOR (14), S2215Y 
mTOR (22), E2419K mTOR (24) or R2505P mTOR (25) and subjected to various treatments 
before cell lysis and detection of mTORC1 signaling via immunoblotting. A&C) 24 hours 
after cotransfection with an empty vector or mTOR construct and Flag-4EBP1, cells were 
starved for 1.5 hours in amino acid-free DMEM with 10% dialyzed serum. Cells were then 
pre-treated with 30 µM FIPI for 30 minutes and switched to growth media containing 30 µM 
FIPI for an additional 30 minutes. B) Ratios of average pT389-S6K1 to total S6K1 signal 
intensities from 4 independent experiments conducted as in A. Intensities were quantified by 
densitometry and normalized to the +a.a. WT sample. *P ≤ 0.01, one-tailed t-test analysis. 
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Figure III.4. Some hyperactivating mTOR mutations confer PLD1 independence. PLD1 
protein was knocked down in HEK 293 cells using lentiviral delivery of shRNA. After 6 days 
of puromycin selection, cells were transfected with empty vector (EV), wild type mTOR 
(WT), L1460P mTOR (14), S2215Y mTOR (22), E2419K mTOR (24) or R2505P mTOR 
(25) and HA-S6K1 DNA. A) 24 hours after transfection, cells were lysed and mTORC1 
signaling was examined via immunoblotting. B) Quantification of the ratio of pT389-S6K1 
to total S6K1 signal intensities shown in A. Intensities were quantified by densitometry and 
normalized to the control shRNA WT sample. C) 24 hours after transfection, cells were 
starved for 2 hours in amino acid-free DMEM with 10% dialyzed serum and then re-
stimulated with growth media for 30 minutes before cells were lysed and mTORC1 signaling 
was examined via immunoblotting. D) Quantification of the ratio of pT389-S6K1 to total 
S6K1 signal intensities shown in A. Intensities were quantified by densitometry and 
normalized to the control shRNA WT sample. 
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Figure III.5. In vitro kinase activity of S2215Y mTOR does not require PA. A) HEK293 
cells were transfected with WT or S2215Y mTOR for 24 hours before cells were starved in 
growth factor-free media for 18hrs. Recombinant mTORC1 complexes were isolated by 
immunoprecipitation with an AU1 antibody and incubated with vesicle buffer or PA vesicles 
for 15 minutes before being subjected to an in vitro kinase assay with a GST-S6K1 substrate. 
B) Quantification of the pT389-GST S6K1 peptide signal intensities from three independent 
experiments conducted as in A. Intensities were quantified by densitometry and normalized 
to the average value from the reactions containing WT mTOR and vesicle buffer. *P ≤ 0.05, 
two-tailed t-test analysis comparing WT + PA or S2215Y +PA samples to their +Buffer 
controls. 
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Figure III.6. R2505P promotes hyper-autocatalytic mTOR activity. HEK 293 cells were 
transfected with empty vector (EV), wild type mTOR (WT), L1460P mTOR (14), S2215Y 
mTOR (22), E2419K mTOR (24) or R2505P mTOR (25) and Flag-4EBP1 for 24 hours. 
Cells were then for 1.5 hours in amino acid-free DMEM with 10% dialyzed serum and pre-
treated with 30 µM FIPI for 30 minutes, or were starved for 2 hours in the presence of 0.3% 
1-butanol. Cells were re-stimulated for an additional 30 minutes by switching them to growth 
media or growth media containing 30 µM FIPI or 0.3% 1-butanol. Cells were lysed and 
mTOR autophosphorylation of S2481 was examined by immunoblotting. 
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Figure III.7. Locations within mTORC1 of the residues carrying point mutations for 
this study. All four mutated residues are colored pink and represented as spheres. L1460 is 
located at the beginning of the FAT domain (blue), E2419 and R2505 both reside within the 
C-lobe of the kinase domain (purple) near the junction with the FAT domain, and S2215 is 
buried at the base of the kinase domain (purple) behind the FAT domain. Refer to Figure I.3 
for other color codes. This image was created with The PyMOL Molecular Graphics System, 
Version 1.8 Schrödinger, LLC., using the mTORC1 structural file (PDBID: 5FLC) deposited 
in the RCSB Protein Data Bank (Aylett et al. 2016).
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Figure III.8. Mutations E2419K and R2505P may affect the orientation of kα9b and 
kα10. Access to the mTORC1 catalytic cleft is obstructed by the kinase C-lobe (purple) and 
mLST8 (gold), the FRB domain (cyan) and FKBP12 in complex with rapamycin (pink), and 
the kα9b helix of the kinase domain (highlighted in yellow). kα9b is connected to kα10 by an 
unstructured segment that connects the residues highlighted in red. Mutating E2419 
(highlighted in pink) or R2505 (pink residue in kα10) may change the structure or orientation 
of kα9b or kα10. This image was created with The PyMOL Molecular Graphics System, 
Version 1.8 Schrödinger, LLC., using the mTORC1 structural file (PDBID: 5FLC) deposited 
in the RCSB Protein Data Bank (Aylett et al. 2016). 
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Figure III.9. S2215 Allows for a tight helical turn. S2215 (shown as pink sticks) allows a 
small segment of the kinase domain to make a sharp turn back toward the FRB domain 
(cyan). The kinase domain is colored purple here with the sharp turn highlighted in yellow. 
This image was created with The PyMOL Molecular Graphics System, Version 1.8 
Schrödinger, LLC., using the mTORC1 structural file (PDBID: 5FLC) deposited in the 
RCSB Protein Data Bank (Aylett et al. 2016). 
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Figure III.10. S2215Y may affect the architecture of mTORC1’s catalytic cleft. Mutating 
S2215 (highlighted in bring pink) to tyrosine would disrupt the sharp helical turn and 
manipulate the position and/or orientation of the following unstructured segment, beta sheets, 
and alpha helix (all highlighted in yellow). The proximity of these regions to the catalytic 
cleft and to the substrate scaffold, raptor (shown in olive on the left) suggests that their 
orientation could easily influence substrate access to the catalytic cleft. This image was 
created with The PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC., using 
the mTORC1 structural file (PDBID: 5FLC) deposited in the RCSB Protein Data Bank 
(Aylett et al. 2016). 
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CHAPTER IV. CONCLUSIONS AND PERSPECTIVE 
 
IV.1. mTOR Activation 
For well over a decade, it has been evident that mTOR phosphorylates protein 
substrates in response to growth factor and amino acid signals. A great deal has been 
discovered by several groups over the years regarding the molecular mechanisms and the 
distinct homodimeric complex (mTORC1) that are involved this signaling. Our group has 
been particularly instrumental in identifying the role of PA in activating mTORC1. By the 
time I joined the investigation, my predecessors had already demonstrated that PA competes 
with rapamycin for binding to the FRB domain of mTOR (Fang et al., 2001) and activates 
mTORC1 signaling by displacing the endogenous inhibitor FKBP38 (Yoon et al., 2011a), as 
well as proving that the PA-producing enzyme PLD1 is an effector of the mTOR mediator 
Rheb (Sun et al., 2008) and is required for mTOR activation by amino acids (Yoon et al., 
2011b). These discoveries notwithstanding, our understanding mTOR activation by PA 
remained incomplete. 
A comprehensive effort to identify other protein interactions with mTOR affected by 
PA revealed that mTOR binding by the endogenous inhibitor, DEPTOR, may be reduced by 
PA. Together with a colleague, I investigated this further and confirmed that DEPTOR is 
displaced from both mTOR complexes by the addition of exogenous PA. We discovered that, 
within cells, PA produced in response to growth factors or amino acids specifically displaces 
DEPTOR from mTORC1 to mTORC1 signaling. Furthermore, we demonstrated that the 
ability of DEPTOR to bind mTOR’s FRB domain and activate mTORC1 is specific to the 
unsaturated PA species that are preferentially produced by PLD1. This study revealed, for the 
first time, how mTORC1 that is bound by DEPTOR is rapidly activated such that it can then 
go on to phosphorylate DEPTOR and trigger the inhibitor’s degradation as was already well 
described. 
How DEPTOR binds to and inhibits mTORC1 remains somewhat nebulous. Peterson 
et al. demonstrated that the FAT domain of mTOR is the minimal region bound by the PDZ 
domain of DEPTOR (Peterson et al., 2009). More recently, independent investigation into the 
mechanism of mTOR hyperactivation revealed that point mutations at mTOR residues 1459, 
1460, 1483, or 2505 significantly disrupt mTOR interaction with DEPTOR. 2505, which is 
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not part of the minimal DEPTOR binding region of mTOR, does reside near the interface 
between the FAT domain and mTOR’s catalytic cleft in the recently published mTORC1 
structure (Aylett et al., 2016). Thus, it appears that DEPTOR binds to the helices in TRD2 of 
mTOR’s FAT domain but also extends across the FAT domain toward R2505 of the C-lobe 
and possibly even toward the catalytic cleft. Interaction between TRD1 of mTOR’s FAT 
domain and the C-lobe of the kinase domain is suspected to be important for mTOR’s 
activity. Perhaps DEPTOR inhibits mTOR by reversibly disrupting this interaction, or 
perhaps it imposes steric hindrance by extending all the way across the FAT domain and C-
lobe to mTOR’s catalytic cleft. Obtaining the protein structure of DEPTOR will inevitably 
shed more light on its mechanism of mTOR inhibition and may even illuminate some 
differences between the regulation of mTORC1 and mTORC2. 
While it is clear from previous studies that reduced DEPTOR binding is not the only 
mechanism by which point mutations hyperactivate mTOR, there has been very little 
investigation into other mechanisms. By manipulating either the activity or protein level of 
PLD1 in cells expressing mTOR carrying individual point mutations, I identified, for the first 
time, that PA-independence is a mechanism of mTOR hyperactivation in cells and in vitro. 
Interestingly, none of the three point mutations that confer PA-independence are located near 
the FRB domain of mTOR. It seems most likely that the S2215Y mutation, which confers the 
most complete PA-independence by far, does so by shifting the orientation of small segments 
of the kinase domain at the base of the FRB domain or at the front face of the catalytic cleft. 
That such a shift could render mTOR independent of PA binding suggests that a 
conformational change that promotes cleft access may be a major dimension of mTORC1 
activation by PA. 
In contrast to the S2215Y mutation, I found that the hyperactivity of mTOR 
containing R2505P toward the substrates S6K1 and 4EBP1 is as dependent on PA as WT 
mTOR. It is interesting to note that residue 2505 falls within the region of mTOR shown to 
be required for interaction with Rheb (Long et al., 2005). It will be interesting to see what 
effect, if any, the R2505P mutation has on mTOR interaction with Rheb. 
Rheb and PLD1 are known to be the mediators of growth factor signals immediately 
upstream of mTORC1. Interestingly, this process requires a permissive amino acid signal that 
is believed to be communicated via two parallel pathways. In the presence of amino acids, 
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the Rag pathway recruits mTORC1 to the lysosome, via Rag-raptor interaction, while the 
Vps34 pathway activates mTORC1 by promoting PLD1 translocation to the lysosomal 
surface. It has been demonstrated that Rheb binds mTOR regardless of GTP-bound state 
(Long et al., 2005) but cannot activate mTORC1 without GTP binding (Long et al., 2007), 
and that GTP-Rheb binds and activates PLD1 (Sun et al., 2008). Additionally, PLD1, which 
mediates mitogenic activation of mTORC1 (Fang et al., 2003), requires Rheb to activate 
mTORC1 in response to growth factors (Yoon et al., 2011b). Furthermore, amino acid 
withdrawal inhibits the interaction of mTOR with either WT or nucleotide-deficient Rheb 
(Long et al., 2005). Taken together, these data point to a mechanism whereby amino acids 
trigger Rag-mediated recruitment of mTORC1 to the lysosomal surface where it meets and 
binds to Rheb. GTP-Rheb, prevalent in growth factor-stimulated cells, then binds and 
activates PLD1 that has been recruited to the lysosome through the activity of Vps34, 
resulting in the production of PA close enough to bind and activate mTOR before the lipid is 
degraded. This mechanism is consistent with our observation that mTORC1 activation by 
amino acids, while independent of growth factors, results in a milder extent of mTORC1 
activity compared to that achieved with both upstream signals. Whether or not Rheb is 
required for PLD1 activation of mTORC1 in response to amino acids has not, to my 
knowledge, been investigated. 
Several years ago, Avruch et al. proposed a very similar mechanism of mTOR 
activation by Rheb (Avruch et al., 2009). At the same time, the authors reported that raptor-
substrate binding is unaffected by cellular condition, unless raptor is incorporated into 
mTORC1, as which point the raptor-substrate interaction is indeed dependent on cellular 
condition. What can we make of this? Given the close proximity of raptor to mTOR’s 
catalytic cleft, and the considerable steric hindrance surrounding the cleft, it seems likely that 
to create sufficient space for substrates to bind raptor and reside within the catalytic cleft, 
changes in mTOR’s conformation must occur – presumably in response to Rheb-GTP and/or 
PA binding. Interestingly, this explanation implies that raptor’s role in mTORC1 signaling is 
not to recruit a substrate, per se, but rather to hold the substrate in place so that the phosphate 
transfer can occur.  
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IV.2. Implications for Cancer Therapy 
 Since the identification of DEPTOR as an endogenous mTOR inhibitor, a number of 
studies, including my own, have dissected mechanisms of DEPTOR regulation while others 
have reported correlation between DEPTOR levels and cancer. Interestingly, mTORC1 
carrying the mutation L1460P exhibits reduced DEPTOR binding and hyper-catalytic activity 
that is correlated with cancer (Grabiner et al., 2014), and yet there are reports of high 
DEPTOR expression resulting in mTOR inhibition that is also correlated with cancer 
(Parvani et al., 2015; Wei et al., 2015).  
Still, the majority of studies investigating a connection between DEPTOR and cancer 
indicate that DEPTOR plays a protective role (Chen et al., 2015; Liu et al., 2015; Obara et 
al., 2015; Wei et al., 2015), most likely by inhibiting hyperactive mTOR signaling and thus 
preventing oncogenic reduction of autophagy (Reiling and Sabatini, 2006). In light of this, 
several groups have proposed the use of pharmacological inhibition of ubiquitin ligase-
mediated DEPTOR degradation as a cancer therapy (Chen et al., 2015; Zhao and Sun, 2012). 
This approach certainly warrants pursuit, but it will have to be carried out with the 
consideration that DEPTOR-related therapies will probably offer limited success in patients 
with an mTOR point mutation that reduces DEPTOR binding. 
 Some of the confusion regarding DEPTOR’s divided role in cancer is probably due, 
in part, to the fact that DEPTOR inhibits both mTOR complexes. mTORC1 and 2 regulate 
distinct cellular processes, all of which play some role in the progression or suppression of 
cancer (Laplante and Sabatini, 2012). In fact, our inability to pharmacologically inhibit one 
mTOR complex for a long period of time without also inhibiting the other may 
simultaneously limit the efficacy and increase the side effects of therapeutic mTOR 
inhibition in cancers arising from hyperactivation of one particular complex. For this reason, 
specifically targeting mTORC1 activity via pharmacological inhibition of the mTORC1 
mediator, PLD1, is an intriguing and promising strategy. However, I have demonstrated that 
select cancer-associated point mutations in mTOR promote hyperactive mTOR signaling 
regardless of PLD1 activity. Therefore, the presence of such point mutations should be taken 
into account when considering PLD1 inhibition as a therapeutic approach, lest the treatment 
inadvertently result in selection for the oncogenic, PLD1-independent mTOR expressing 
cells. 
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 Finally, it is important to note that I have described, for the first time, a major 
increase in the autocatalytic activity of mTOR conferred by the cancer-associated point 
mutation R2505P. The inconsistencies between the activity of R2505P mTOR toward its 
substrates (S6K1 and 4EBP1) and its own autophosphorylation are striking and they carry 
significant implications. Certainly, these inconsistencies corroborate other evidence that 
substrate and autophosphorylation are differentially regulated within mTOR. Furthermore, 
this discovery calls into question the reliability of P-S2481 mTOR as a biomarker of 
oncogenic cancer signaling. 
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APPENDIX A. MTOR: SUBCELLULAR LOCALIZATION AND FUNCTION  
 
A.1. Introduction 
As a master-regulator of cell signalling, mTOR couples a variety of intra- and 
extracellular signals with the phosphorylation of multiple substrates to control arrange of 
cellular processes including transcription and protein synthesis. Not surprisingly, mTOR 
signalling is found to be significantly dysregulated in the ten most common cancers 
(Dazert and Hall, 2011) Mutations in mTOR itself have only been reported more recently, 
indicating the necessity of the entire regulatory context in maintaining tight regulation of 
cell growth. 
It has been clear for many years that mTOR responds to amino acid availability and 
growth signals by enabling downstream changes in protein production and cell 
morphology. Many of these responses, whether they involve the accumulation of increased 
cell mass required for cell division or the expression of new genes, rely on protein 
translation and increased levels of translational machinery. In healthy and actively 
growing animal and plant cells, the production of rRNA accounts for about 50% of the 
total transcription. During times of nutrient deficiency, however, this energy-costly level 
of translational machinery must be down regulated. When uncontrolled, the production of 
translational machinery has been implicated as an oncogenic factor in a variety of cancers. 
(Johnson et al., 2008; Marshall et al., 2008; Pavon-Eternod et al., 2009; Ruggero and 
Pandolfi, 2003). The most established mediator of ribosome biogenesis control is the 
multi-subunit complex mTORC1, composed of mTOR, a scaffold protein called raptor, 
and other regulatory subunits. In nutrient rich conditions, mTORC1 enables ribosomal 
protein translation via phosphorylation of S6K1 and 4EBP1. Interestingly, this process 
requires both cytoplasmic and nuclear localization of mTOR, indicative of cytoplasmic-
nuclear shuttling (Bachmann et al., 2006; Kim and Chen, 2000; Park et al., 2002).  
The nuclear presence of mTOR was first reported over 10 years ago (Kim and Chen, 
2000) and, since then, numerous ChIP and transcriptional assay experiments have reported 
that both mTOR and raptor are bound to the promoters of rRNA and tRNA genes and are 
required for nutrient-mediated transcription of translational machinery (Kantidakis et al., 
2010; Mayer et al., 2004; Michels et al., 2010; Shor et al., 2010; Tsang et al., 2010). Yet, 
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most considerations of mTORC1 regulation have overlooked the nucleus entirely, most 
often analyzing total cellular mTORC1 as a whole. Consequently, it remains unclear the 
extent to which the canonical mTORC1 pathway (see Figure A.1) regulates nuclear 
mTORC1. 
There have also been reports of nuclear mTORC2 (Rosner and Hengstschläger, 2008; 
Singh et al., 2010), though the complex was long believed to predominantly reside at the 
plasma membrane, which is largely considered to be the site of Akt phosphorylation (Gao 
et al., 2011; Hill et al., 2002; Partovian et al., 2008). Recently, however, mTORC2 was 
described to be predominantly localized to the endoplasmic reticulum (ER) (Boulbés et al., 
2011). Shortly after, another study was published that demonstrated recruitment of 
mTORC2 to mitochondrial associated membranes (MAMs) by growth factors (Betz et al., 
2013). It may be that MAM is the main hub for mTORC2 signaling to mitochondrial and 
ER proteins (Betz and Hall, 2013). There is still much to discover and delineate regarding 
the roles and regulation of mTORC2 throughout the cell. 
 
A.2. Effect of Phosphatidic Acid Species on mTORC2 
 
A.2.1. Background 
 Nucleating mTORC1 and mTORC2, mTOR can regulate a host of different cellular 
processes by responding to complex-specific stimuli and phosphorylating substrates 
unique to complex 1 or complex 2. For example, growth factors stimulate phosphorylation 
of both mTORC1 and mTORC2 substrates (Kim et al., 2002) (Razmara et al., 2013), while 
amino acid signals upstream of mTOR have been shown to activate mTORC1 specifically 
(Sancak et al., 2008; Yoon et al., 2011a), which results in the phosphorylation of S6K1 
and 4EBP1 leading to protein translation and cell growth. PLD1, whose activity is 
upregulated in response to both growth factors and amino acids, is a positive regulator of 
mTORC1. Unsaturated PA produced by PLD1 specifically binds to the FRB domain of 
mTOR, displaces endogenous mTOR inhibitors, and activates mTORC1 in vitro without 
affecting mTORC2. There is evidence, however, that saturated PA species produced by 
other enzymes inhibit mTORC2 (Zhang et al., 2012). 
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A.2.2. Results 
 The mass spectrometry screen described in Chapter II identified the mTORC2 
component mSin1 as a protein whose interaction with mTOR might be disrupted by 
C8PA. Given that mSin1 is required for mTORC2 stability and that saturated PA species 
were reported to disrupt mTORC2, we hypothesized that saturated PA species might 
disrupt mSin1-mTOR interaction. To investigate this possibility, I treated cells with a 
variety of saturated and unsaturated PA species and isolated mTORC2 complexes by 
immunoprecipitating rictor. As shown in Figure A.2, I consistently saw that that saturated 
PA species had no effect on mSin1 incorporation into mTORC2. Saturated PA species, on 
the other hand, caused a significant reduction in the amount of rictor and mSin1 
immunoprecipitated. This reduction appears to the be the result of decreased cellular rictor 
and mSin1 levels, since the rictor and mSin1 signals were decreased in the cell lysates as 
well. Interestingly, this effect of saturated PA species seems to be greater in asynchronous 
cells than in serum starved cells. 
 It is unlikely that the decreased rictor and mSin1 levels are a result of degradation 
induced by unsaturated PA species because the effect is seen within 30 minutes of PA 
addition and was unaffected by inhibition of the proteasome with MG231 (data not 
shown). I hypothesized, therefore, that unsaturated PA species were causing a reduction in 
rictor and mSin1 detection, rather than a reduction in total protein level. Since I was using 
a mild detergent to lyse my cells, I suspected that soluble rictor and mSin1 might move to 
saponin-resistant membranes, upon the addition of saturated PA, and therefore be 
eliminated from my cell lysates. To investigate this possibility, I treated the cells 
unsaturated or saturated PA and lysed the cells with detergents of different strengths. I 
observed that, indeed, unsaturated PA caused a reduction in the amount of rictor protein 
obtained by lysis with saponin, compared to the amount of rictor in cells treated with 
saturated PA or cells lysed with stronger detergents (Figure A.3A). As shown in Figure 
A.3B, the levels of isolated mTORC2 were relatively unaffected by the type of PA species 
used when cells were lysed with CHAPS-containing lysis buffer.  
Recent reports show mTORC2 association with mitochondria, the ER, and MAMs. 
It is intriguing to think that unsaturated PA recruits mTORC2 to saponin-resistant 
membrane domains associated with these organelles/structures. I tried to investigate this 
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possibility using immunofluorescent detection of endogenous rictor and a mitochondrial 
marker protein. The rictor signal perfectly co-localized with the mitochondrial signal 
when I used antibodies for both proteins, regardless of 16:0-18:1 PA treatment (Figure 
A.4A). I did not observe this strong punctate pattern all the way around the nucleus when I 
stained cells with the rictor antibody alone (Figure A.4B) – only when I co-stained with 
the mitochondrial antibody. Unfortunately, it appears that the rictor primary antibody I 
used interacts with the mitochondrial antibody, or that the anti-rabbit secondary antibody 
cross reacts with the mouse mitochondrial antibody. I did notice repeatedly that the 
nuclear signal from the endogenous rictor antibody decreased slightly after treatment with 
16:0-18:1 PA. 
 Interestingly, in two preliminary experiments, I observed that cell stimulation with 
a variety of PA species stimulate phosphorylation of the mTORC2 substrate Akt (Figure 
A.5). This is contrary to the report by Zhang et al. that saturated PA species inhibit 
mTORC2 signaling (Zhang et al., 2012), and is somewhat inconsistent with the report that 
PA does not activate mTORC2 in vitro (Yoon et al., 2011b). Given the apparent 
relationship between PA, mTORC2, and membrane recruitment, it is possible that the 
cellular context is very important in determining the effect on PA species on mTORC2 
function. 
 
A.3. Nuclear Localization of mTORC Components 
 
A.3.1. Background 
Defined by the incorporation of a scaffold protein called raptor, mTORC1 mediates 
nutrient-dependent cell growth and proliferation through a number of well-studied 
cytoplasmic signaling pathways. Intriguingly, one such pathway, which controls the 
translation of ribosomal proteins and elongation factors in the cytoplasm, has been shown 
to require the nuclear import of mTOR (Bachmann et al., 2006; Kim and Chen, 2000). The 
discovery that mTOR exists in within both mTORC1 and mTORC2 warrants investigation 
of the possibility and role of nuclear shuttling activity by mTORC1&2 components or 
complexes themselves. 
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A.3.2. Results 
 Surprisingly, I detected very little nuclear accumulation of endogenous mTOR by 
immunofluorescence after treatment with an inhibitor of nuclear export, leptomycin B 
(LMB) (Figure A.6A). I did detect some nuclear accumulation of Flag-mTOR (Figure 
A.6B), however the immunofluorescent pattern was quite different between endogenous 
mTOR and Flag-mTOR under identical treatment conditions. I consistently detect the 
accumulation of HA-raptor within the nucleus of HEK293 cells after LMB treatment 
(Figure A.7A). Preliminary data suggest that neither Flag-mTOR nor HA-raptor nuclear 
import require interaction with raptor or mTOR, respectively, since rapamycin treatment, 
which was shown to disrupt raptor-mTOR interaction (Kim et al., 2002; Oshiro et al., 
2004), had no effect on nuclear accumulation (Figure A.7B). Overexpression of raptor 
results in the inhibition of mTORC1 signaling to S6K1, as reported by Kim et al. and 
shown in Figure A.III.2C (Kim et al., 2002). Interestingly, this inhibition was significantly 
less when I overexpressed raptor protein that was targeted to the nucleus with a nuclear 
localization signal (NLS) (Figure A.7C). 
 
A.4. Regulation of a Nuclear mTOR Function 
 
A.4.1. Background 
Since the identification of nuclear mTOR (Kim and Chen, 2000), its most 
extensively studied role has been the upregulation of RNA polymerase III (pol III) activity 
via direct phosphorylation and inactivation of the pol III repressor, Maf1 (Kantidakis et 
al., 2010; Michels et al., 2010; Shor et al., 2010). However, the mechanism of this nuclear 
mTORC1 response to growth factors and its dependence on the entire canonical pathway 
have not been investigated. It is possible that nuclear mTORC1 is regulated by the same 
pathway as the cytoplasmic pool until it translocates to the nucleus. However, our current 
understanding is that cytoplasmic mTORC1 must remain associated with lysosomes via 
the Rag/Ragulator complex in order to phosphorylate substrates. Therefore, to have active 
mTORC1 within the nucleus likely requires an alternative mechanism. Identification of 
growth factor or nutrient-mediated control of mTORC1 that is in some way independent of 
the canonical pathway may indicate the existence of novel mTOR regulators. The 
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existence of a novel regulatory pathway is warranted, in part, by a separate mTORC2 
pathway (Sarbassov et al., 2004) and a recently described negative role of Raptor and 
Rheb in skeletal myogenesis (Ge et al., 2011) both of which share at least some upstream 
regulators with the mTORC1 pathway. Bifurcated cytoplasmic and nuclear regulation 
could potentially be exploited to generate specific therapeutics tailored to one branch of 
the pathway or the other. 
 
A.4.2. Results 
 As shown in Figure A.8, I confirmed that the phosphorylation of Maf1 is indeed 
mediated by mTORC1; inhibition of mTORC1 activity via acute rapamycin treatment 
(Figure A.8A) or shRNA-mediated raptor knockdown (Figure A.8B) inhibited the 
phosphorylation of Maf1 as detected by the collapse of the electrophoretic Maf1 bandshift 
observed in control cells with mTORC1 activity. mTORC1 phosphorylates Maf1 in 
response to stimulation with either growth factors or amino acids (Figure A.8C). Whether 
amino acids are required for the phosphorylation of Maf1, as they are for the 
phosphorylation of cytoplasmic substrates, was not investigated. 
 In order to identify the proteins mediating signals upstream of Maf1 
phosphorylation, I manipulated the canonical growth factor- and amino acid-sensing 
pathway upstream of mTORC1 in HEK293 cells. Intriguingly, knocking down TSC2, a 
canonical negative regulator of mTORC1 activity, was sufficient to promote a subtle 
increase in serum-stimulated phosphorylation of S6K1 but had no detectable effect on 
Maf1 phosphorylation (Figure A.9A). In line with this finding, overexpressing Rheb, a 
canonical positive mediator of mTORC1 activation by growth factors, resulted in mild 
phosphorylation of S6K1 in serum-starved cells without affecting the bandshift of Maf1 
(Figure A.9B). Without a phoshpho-specific Maf1 antibody, I cannot rule out the 
possibility that an increase in Maf1 phosphorylation has occurred in these experiments 
that is too subtle to detect by electrophoretic bandshift. I next interrogated the role of the 
canonical amino acid-sensing mTORC1 pathway in amino acid-stimulated Maf1 
phosphorylation. As shown in Figure A.10A, knockdown of hVps34, RagC&D, or the 
vATPase componenets V0 and V1 caused a significant inhibition of S6K1 
phosphorylation as expected and also caused a mild inhibition of Maf1 phosphorylation. 
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Canonical activation of mTORC1 by amino acids culminates at the surface of the 
lysosome. I found that inhibiting the integrity of the lysosome with the chemicals 
concanamycin A or chloroquine inhibited amino acid-stimulated phosphorylation of Maf1, 
further corroborating the role of the canonical amino acid-sensing pathway in Maf1 
phosphorylation by mTORC1 (Figure A.10B). 
 Considering the subtlety of the changes I observed in Maf1 phosphorylation when 
manipulating the amino acid-sensing pathway, I wondered if they reflected regulation of 
only a fraction of the Maf1 in the cell. To investigate this, I assessed Maf1 localization in 
HEK293 cells using immunofluorescent imaging. Detection of Maf1 by 
immunofluorsescence revealed that Maf1 is distributed throughout the nucleus and the 
cytoplasm of HEK293 cells. This distribution appears unaffected by starvation or 
stimulation (Figure A.11A), suggesting that Maf1 is present in the cytoplasm regardless of 
mTORC1 activation. It is, therefore, possible that the Maf1 in the cytoplasm is 
phosphorylated when it associates with canonical mTORC1 at the lysosome, while the 
nuclear Maf1 is regulated independently. I then investigated Maf1 localization in HeLa 
cells and found that Maf1 localization is predominantly nuclear in serum-starved HeLa 
cells but rapidly moves to the cytoplasm after serum stimulation. Thus, Maf1 localization 
and regulation is cell type-dependent. I went on to confirm that serum-stimulated Maf1 
export from the nucleus is dependent on its phosphorylation by mTORC1, since it is 
inhibited by acute rapamycin treatment (Figure A.11B). 
I went on to investigate the role of amino acids in regulating Maf1 phosphorylation 
in HeLa cells. As shown in Figure A.12A, amino acid stimulation resulted in a very 
significant bandshift, indicating that nearly all the Maf1 in HeLa cells is phosphorylated in 
response to amino acid stimulation. Intriguingly, Maf1 phosphorylation in HeLa cells 
appears unaffected by chemical inhibition of the canonical mTORC1 pathway with 
concanamycin A, chloroquine, or 1-butanol (Figure A.12A&B). Together with the results 
from HEK293 cells, these preliminary data from HeLa cells suggest that the canonical 
mTORC1 pathway may mediate phosphorylation of cytoplasmic, but not nuclear, Maf1. 
The possibility that nuclear Maf1 is regulated independently of the canonical mTORC1 
pathway is a very exciting possibility. This would make Maf1 the first mTORC1 substrate 
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found to be regulated independent of the canonical pathway, and this could significantly 
change our understanding of mTORC1 regulation. 
 
A.5. Materials and Methods 
 
A.5.1. Antibodies and Other Reagents 
All antibodies used in this study were obtained from the following commercial 
sources: anti-Flag M2 from Sigma-Aldrich, anti-Maf1 (sc-98715) and anti-rictor for 
immunofluorescence (sc-99004) from Santa Cruz Biotechnology, anti-mSin1 (A300-910A) 
and anti-rictor for IP (A300-459A) from Bethyl Laboratories, Inc., anti-Myc (9E10.2) and 
anti-HA (16B12) from Covance, Alexa Fluor 594 anti-mouse and 488 anti-rabbit from Life 
Technologies (A11020 and A11006), anti-mitochondria from Abcam (ab3298), all other 
secondary antibodies from Jackson ImmunoResearch, and P-S6K1 (9206), rictor (9476), 
mTOR (2983), hVps34 (3811), P-NDRG1, P-473 Akt from Cell Signaling. Rapamycin and 
leptomycin B (LMB) were purchased from LC Laboratories. Protein G-agarose was from 
Millipore. All lipids were in chloroform and were purchased from Avanti Lipids. All other 
reagents were purchased from Sigma-Aldrich. 
 
A.5.2. Plasmids 
Flag-mTOR and myc-S6K1 plasmids were described previously (Vilella-Bach et al., 
1999), as was Flag-Rheb (Sun et al., 2008). pRK5-HA-raptor (plasmid 8513) was obtained 
from Addgene (Kim et al., 2002). HA-NLSraptor was obtained by cutting pRK5-HA-raptor 
with SalI and inserting an NLS linker with forward strand:  
5’TCGAAGAAGAAGCGGAAGGTGGAGTCG3’ and reverse strand: 
5’TCGACGCCTCCACCTTCCGCTTCTTCT3’. 
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A.5.3. Cell Culture 
HEK293, CV1, and HeLa cells were maintained in growth media comprised of 
DMEM (4.5g glucose/L) containing amino acids and 10% fetal bovine serum (FBS),  at 37 
°C with 5.5%. Transfections were performed with Polyfect (Qiagen) following the 
manufacturers’ recommendations. Serum starvation was achieved by incubating cells in 
serum-free DMEM overnight. Amino acid starvation was achieved either by serum starving 
the cells overnight and then incubating them in amino acid-free DMEM for 2hours, or by 
starving the cells in amino acid-free DMEM with and 10% dialyzed FBS for the indicated 
lengths of time. Growth media was used for both serum and amino acid stimulations. 
 
A.5.4. Cell lysis, Immunoprecipitation (IP) and Western Blotting 
For IP, cells were lysed in ice-cold lysis buffer (40 mM HEPES, pH7.4, 120 mM 
NaCl, 10 mM sodium pyrophosphate, 50 mM NaF, 2 mM EDTA, 1x protease inhibitor 
cocktail (PIC) (Sigma-Aldrich), and 0.05% saponin or 0.3% CHAPS as indicated). To make 
lysates for western blotting only, cells were lysed in 20 mM Tris-HCl at pH7.5, 0.1 mM 
Na3VO4, 25 mM NaF, 25 mM glycerophosphate, 2mM EGTA, 0.3% Triton X-100. Upon 
cell lysis, the lysate supernatant was collected after centrifugation at 10,000g for 10 minutes, 
and subjected to IP at 4 °C a rictor antibody and protein G agarose beads. Lysates and IP 
products were mixed with SDS sample buffer containing 5% final concentration of 2-
mercaptoethanol. All samples were boiled for 5 min and proteins were resolved on SDS-
PAGE and transferred onto PVDF membranes (Millipore). Antibody incubations were 
performed following the manufacturers’ recommendations. Detection of horseradish 
peroxidase-conjugated secondary antibodies was performed with chemiluminescence 
solution (100 mM Tris-HCl, 0.009% H2O2, 225 µM coumaric acid, 1.25 mM luminol). 
Images were developed on x-ray films. 
 
A.5.5. Immunofluorescence Imaging 
HEK293 cells cultured on poly-L-lysine-coated glass coverslips were transfected and 
treated as indicated in figure legends, followed by fixation in 3.7% paraformaldehyde and 
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permeabilization with 0.1% Triton X-100. Primary antibody incubation was performed in 3% 
BSA/PBS at 4 degrees Celsius overnight, followed by incubation with the appropriate Alexa 
Fluor antibody and DAPI in 3% BSA/PBS for 30 min at room temperature. Images were 
captured using a 60X oil immersion lens. 
 
A.5.6. Lipid Vesicle Preparation 
All lipids were purchased from Avanti Polar Lipids, Inc. in chloroform. PA vesicles 
were prepared as previously described (Yoon et al., 2011b) by water bath sonication, at a 
final concentration of 3 mM. 
 
A.5.7. Lentivirus-mediated RNAi 
Lentiviral shRNA plasmids used in this study were in the pLKO.1puro vector from 
The RNAi Consortium (TRC; Sigma-Aldrich). shRNA clones for hVps34 
(TRCN0000037794), Rag C (TRCN0000072874), Rag D (TRCN0000059533), raptor, and 
the negative control shRNA (scrambled hairpin sequence) were previously described (Yoon 
et al., 2011a). Lentivirus packaging was performed by cotransfecting pLKO-shRNA, pCMV-
dR8.91, and pCMV-VSV-G into 293T cells using TransIT-LT1 (Mirus Bio LLC) at 0.5, 
0.45, and 0.05 µg, respectively (for 1 well in a 6-well plate). Media containing viruses were 
collected 48 h after transfection. Cells were infected with the viruses in the presence of 6 
mg/ml polybrene for 24 h and were then subjected to selection by 1.5 µg/ml puromycin for 
the indicated number of days. 
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A.6. Figures 
 
 
Figure A.1. The canonical mTORC1 pathway. Growth factor signals (mediated by the 
TSC/Rheb axis shown in green) and amino acid sufficiency (mediated by the Vps34 and Rag 
pathways shown in light blue) activate mTORC1 phosphorylation of cytoplasmic substrates 
like S6K1 and 4EBP1.  
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Figure A.2. Unsaturated PA species reduce the amount of mTORC2 components 
detected in cell lysates. HEK293 cells were treated with vesicles of unsaturated (black) or 
saturated (red) PA species for 30 minutes before being lysed in HEPES/Saponin buffer. 
mTORC2 complexes were immunoprecipitated (IPed) with an antibody against rictor and 
protein levels were analyzed by SDS-PAGE and western blotting. A) Cells were serum 
starved overnight before the addition of PA vesicles. B) PA vesicles were added directly to 
asynchronous cells in normal growth media. 
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Figure A.3. The effect on unsaturated PA species on levels of mTORC2 components in 
cell lysates is sensitive to detergents. HEK 293 cells were serum starved overnight before 
being treated with unsaturated (black) or saturated (red) PA species for 30 minutes. A) Cells 
were lysed in buffers containing the indicated detergents and rictor protein levels were 
analyzed by SDS-PAGE and western blotting. B) Cells were lysed in HEPES/CHAPS buffer 
containing PIC and cell lysates were subjected to IP with an antibody against rictor. Protein 
levels were analyzed by SDS-PAGE and western blotting. 
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Figure A.4. Immunofluorescent detection of endogenous rictor and mitochondria. HEK 
293 cells were fixed, permeabilized, and stained with primary antibodies against endogenous 
rictor and a mitochondrial protein (A) or rictor alone (B). Cells were then incubated with 
anti-rabbit and anti-mouse (A) or only anti-rabbit fluorescent secondary antibodies, mounted, 
and imaged with a 60X oil immersion lens. A) Cells were serum starved overnight; cells on 
the right were then stimulated with 16:0-18:1 PA for 30 minutes before being fixed. B) 
Asynchronous cells were fixed and analyzed. 
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Figure A.5. PA species may affect mTORC2 signaling in cells. HEK 293 cells were serum 
starved overnight or left growing asynchronously as indicated. Cells were treated with 
vesicles of unsaturated (black) or saturated (red) PA species for 30 minutes before being 
lysed in HEPES/Saponin buffer. Protein levels were analyzed by SDS-PAGE and western 
blotting. 
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Figure A.6. Nuclear mTOR may accumulate with LMB treatment.  Asynchronous CV1 
cells were fixed and permeabilized and mTOR localization was examined by 
immunofluorescence with an antibody against endogenous mTOR (A) or an antibody against 
Flag (B). A) Cells were treated with 10ng/mL LMB or the equivalent amount of ethanol for 
12 hours. B) Cells were transfected with Flag-mTOR. 24 hours later, cells were treated as in 
A. 
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Figure A.7. Characterization of nuclear raptor. A) 24 hours after transfection with HA-
raptor, HEK 293 cells were treated with 10ng/mL of LMB or the equivalent volume of 
ethanol for 12 hours. Cells were fixed and permeabilized, and recombinant raptor was 
detected by immunofluorescence with an antibody against HA. B) CV1 cells were 
transfected with Flag-mTOR and HEK 293 cells were transfected with HA-raptor for 24 
hours. The cells were then treated as in A, using an antibody against Flag or HA for 
immunofluorescence. C) HEK 293 cells were co-transfected with HA-raptor and myc-S6K1 
or HA-NLSraptor and myc-S6K1. 24 hours later, cells were switched to DMEM lacking FBS 
overnight. Cells were then stimulated, as indicated, with FBS-containing growth media for 
30 minutes before cells were lysed and proteins were analyzed by SDS-PAGE and western 
blotting. The white asterisk indicates myc-p70S6K1 and the black asterisk indicates 
endogenous p70S6K1. 
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Figure A.8. In HEK293 cells Maf1 is phosphorylated in response to growth factors in an 
mTORC1-dependent manner and in response to amino acids. HEK 293 cells were treated 
as indicated and cell lysates were examined by SDS-PAGE and western blotting. A) Cells 
were cultured in FBS-free DMEM overnight, then treated, as indicated, with 100nM 
rapamycin for 1 hour before being stimulated with growth media with or without rapamycin 
for 30 minutes. B) HEK 293 cells were infected with lentivirus containing shRNA against 
raptor or a scramble control. Cells were selected with puromycin for 4 days before being 
cultured in FBS-free DMEM overnight and stimulated, as indicated, with growth media for 
30 minutes. C) Cells were either cultured in FBS-free media overnight or in amino acid-free 
DMEM containing 10% dialyzed FBS for 2 hours, before being stimulated for 30 minutes 
with growth media.
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Figure A.9. In HEK 293 cells Maf1 phosphorylation is unaffected by the TSC/Rheb 
axis. A) Cells were infected with lentivirus containing shRNA against TSC2 or a scramble 
control. Cells were selected with puromycin for 6 days before being cultured in FBS-free 
DMEM overnight and stimulated, as indicated, with growth media for 30 minutes. Cell 
lysates were analyzed by SDS-PAGE and western blotting. B) 24 hours after starvation with 
Flag-Rheb, cells were cultured in FBS-free DMEM overnight and stimulated, as indicated, 
with growth media for 30 minutes. Cell lysates were analyzed as in A. 
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Figure A.10. In HEK 293 cells Maf1 phosphorylation is regulated by the amino acid-
sensing mTORC1 pathway. A) HEK 293 cells were infected with lentivirus containing 
shRNA against the indicated proteins or a scramble control. After 6 days of puromycin 
selection, cells were cultured in FBS-free DMEM overnight and then in FBS- and amino 
acid-free DMEM for two hours before they were stimulated, as indicated, with growth media 
for 30 minutes. B) HEK 293 cells were cultured in FBS-free DMEM overnight, then 
switched to FBS- and amino acid-free DMEM with DMSO (control), 5mM concanamycin A 
(ConA), or 100mM chloroquine (CQ) for 2 hours. Finally, cells were stimulated for 30 
minutes with growth media with or without the respective inhibitor. Cell lysates from A) and 
B) were analyzed by SDS-PAGE and western blotting. 
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Figure A.11. Regulation of Maf1 localization is cell type-dependent. A) HEK 293 or 
HeLa cells were cultured in FBS-free DMEM overnight and then stimulated with growth 
media for 30 minutes before being fixed and permeabilized. Endogenous Maf1 was detected 
by immunofluorescence with an antibody against Maf1. B) HeLa cells were starved and 
stimulated as in A except that they were treated with 100nM rapamycin for 1 hour before and 
throughout the 30 minutes of serum stimulation. Cells were analyzed as in A. 
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Figure A.12. In HeLa cells Maf1 phosphorylation appears independent of the canonical 
amino acid-sensing mTORC1 pathway. HeLa cells were incubated in amino acid-free 
DMEM containing 10% dialyzed FBS and DMSO or the indicated inhibitors for 4 hours. 
Cells were then stimulated for 30 minutes with growth media in the presence of the indicated 
inhibitors. B) HeLa cells were incubated in amino acid-free DMEM containing 10% dialyzed 
FBS with or without 0.3% 1-butanol for 6 hours. Cells were then stimulated for 30 minutes 
with growth media with or without 1-butanol present. Cell lysates from A) and B) were 
analyzed by SDS-PAGE and western blotting. 
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